WO2005083075A1 - 表皮分化に関与する新規遺伝子、およびその利用 - Google Patents
表皮分化に関与する新規遺伝子、およびその利用 Download PDFInfo
- Publication number
- WO2005083075A1 WO2005083075A1 PCT/JP2005/003458 JP2005003458W WO2005083075A1 WO 2005083075 A1 WO2005083075 A1 WO 2005083075A1 JP 2005003458 W JP2005003458 W JP 2005003458W WO 2005083075 A1 WO2005083075 A1 WO 2005083075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dermokine
- protein
- gene
- polynucleotide
- present
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 426
- 230000004069 differentiation Effects 0.000 title claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 190
- 230000014509 gene expression Effects 0.000 claims abstract description 142
- 210000004027 cell Anatomy 0.000 claims description 172
- 210000002510 keratinocyte Anatomy 0.000 claims description 165
- 238000000034 method Methods 0.000 claims description 132
- 230000000694 effects Effects 0.000 claims description 99
- 102000040430 polynucleotide Human genes 0.000 claims description 98
- 108091033319 polynucleotide Proteins 0.000 claims description 98
- 239000002157 polynucleotide Substances 0.000 claims description 98
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 91
- 229920001184 polypeptide Polymers 0.000 claims description 86
- 150000001875 compounds Chemical class 0.000 claims description 70
- 238000012360 testing method Methods 0.000 claims description 66
- 150000001413 amino acids Chemical class 0.000 claims description 64
- 101000581940 Homo sapiens Napsin-A Proteins 0.000 claims description 63
- 101710134372 Suprabasin Proteins 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 239000013598 vector Substances 0.000 claims description 47
- 108020004414 DNA Proteins 0.000 claims description 41
- 238000012216 screening Methods 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 230000000692 anti-sense effect Effects 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 210000005127 stratified epithelium Anatomy 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 25
- 230000009368 gene silencing by RNA Effects 0.000 claims description 23
- 210000002341 stratified epithelial cell Anatomy 0.000 claims description 23
- 238000013518 transcription Methods 0.000 claims description 22
- 230000035897 transcription Effects 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 21
- 108090000994 Catalytic RNA Proteins 0.000 claims description 20
- 102000053642 Catalytic RNA Human genes 0.000 claims description 20
- 108091092562 ribozyme Proteins 0.000 claims description 20
- 208000017520 skin disease Diseases 0.000 claims description 18
- 206010021198 ichthyosis Diseases 0.000 claims description 15
- 230000035755 proliferation Effects 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- KKVZKYOBQGDKIB-UHFFFAOYSA-N 3-[3-[2-(3,4,5-trimethoxyanilino)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]propanenitrile Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3N(C=4C=C(CCC#N)C=CC=4)C=CC3=CN=2)=C1 KKVZKYOBQGDKIB-UHFFFAOYSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000012228 culture supernatant Substances 0.000 claims description 12
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- 230000029774 keratinocyte migration Effects 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 1
- 206010048222 Xerosis Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 abstract description 37
- 108020004999 messenger RNA Proteins 0.000 abstract description 22
- 238000007901 in situ hybridization Methods 0.000 abstract description 11
- 230000026676 system process Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 161
- 241000699666 Mus <mouse, genus> Species 0.000 description 83
- 102100027343 Napsin-A Human genes 0.000 description 57
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 56
- 102100020889 Suprabasin Human genes 0.000 description 52
- 239000010410 layer Substances 0.000 description 45
- 239000000523 sample Substances 0.000 description 40
- 239000002299 complementary DNA Substances 0.000 description 38
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 32
- 210000003491 skin Anatomy 0.000 description 32
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 239000012634 fragment Substances 0.000 description 24
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 20
- 238000009396 hybridization Methods 0.000 description 20
- 108020001507 fusion proteins Proteins 0.000 description 18
- 230000002441 reversible effect Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 239000011575 calcium Substances 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 101710130746 Dermokine Proteins 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 13
- 238000003119 immunoblot Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 101000872044 Homo sapiens Dermokine Proteins 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 108010033564 involucrin Proteins 0.000 description 11
- 102000007236 involucrin Human genes 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 102000011782 Keratins Human genes 0.000 description 9
- 108010076876 Keratins Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 102000056276 human DMKN Human genes 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000013517 stratification Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 102100033582 Dermokine Human genes 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 7
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 7
- 206010020649 Hyperkeratosis Diseases 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- -1 empoplakin Proteins 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101000872043 Mus musculus Dermokine Proteins 0.000 description 6
- 108091058545 Secretory proteins Proteins 0.000 description 6
- 102000040739 Secretory proteins Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 201000011486 lichen planus Diseases 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 208000000260 Warts Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 201000010153 skin papilloma Diseases 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 4
- 108010070553 Keratin-5 Proteins 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108060008539 Transglutaminase Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 208000009621 actinic keratosis Diseases 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000011712 cell development Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003917 human chromosome Anatomy 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- 102000003601 transglutaminase Human genes 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 3
- 108091000074 Desmoplakin Proteins 0.000 description 3
- 102000029792 Desmoplakin Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 3
- 108010066321 Keratin-14 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100026259 Repetin Human genes 0.000 description 3
- 101710147968 Repetin Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100035785 Acyl-CoA-binding protein Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108010072220 Cyclophilin A Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108010039287 Diazepam Binding Inhibitor Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 description 2
- 101000716721 Homo sapiens Suprabasin Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 101710183391 Keratin, type I cytoskeletal 14 Proteins 0.000 description 2
- 108010065038 Keratin-10 Proteins 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102000008201 Lamin Type A Human genes 0.000 description 2
- 108010021099 Lamin Type A Proteins 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 101000614435 Mus musculus Keratin, type I cytoskeletal 14 Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100037235 Sciellin Human genes 0.000 description 2
- 101710090926 Sciellin Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102000046387 human NAPSA Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- YGLMVCVJLXREAK-MTVMDMGHSA-N 1,1-dimethyl-3-[(1S,2R,6R,7S,8R)-8-tricyclo[5.2.1.02,6]decanyl]urea Chemical compound C([C@H]12)CC[C@@H]1[C@@H]1C[C@@H](NC(=O)N(C)C)[C@H]2C1 YGLMVCVJLXREAK-MTVMDMGHSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000619807 Bos taurus Peroxiredoxin-6 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150083680 CHL1 gene Proteins 0.000 description 1
- 101100150142 Caenorhabditis elegans sprr-2 gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000012695 Ce precursor Substances 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100023795 Elafin Human genes 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108010011042 Envoplakin Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 1
- 101710142059 Free fatty acid receptor 2 Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091027874 Group I catalytic intron Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000454273 Hirashima Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101000976051 Homo sapiens Involucrin Proteins 0.000 description 1
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 101000694030 Homo sapiens Periplakin Proteins 0.000 description 1
- 101000653235 Homo sapiens Protein-glutamine gamma-glutamyltransferase K Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 101710123018 Integrin alpha-M Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 108010084772 LIM Domain Proteins Proteins 0.000 description 1
- 102000005633 LIM Domain Proteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001056472 Mus musculus Keratin, type II cytoskeletal 5 Proteins 0.000 description 1
- 101100234654 Mus musculus Krtdap gene Proteins 0.000 description 1
- 101000940873 Mus musculus Loricrin Proteins 0.000 description 1
- 101100347983 Mus musculus Napsa gene Proteins 0.000 description 1
- 101000694024 Mus musculus Periplakin Proteins 0.000 description 1
- 101100361772 Mus musculus Rptn gene Proteins 0.000 description 1
- 101000716720 Mus musculus Suprabasin Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010081372 NM23 Nucleoside Diphosphate Kinases Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- 102100032209 Nucleoside diphosphate kinase 3 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100027184 Periplakin Human genes 0.000 description 1
- 101710202907 Periplakin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100037925 Prothymosin alpha Human genes 0.000 description 1
- 238000011531 Quantitect SYBR Green PCR kit Methods 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 108020005543 Satellite RNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 102100032250 Trichohyalin Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001172 blastoderm Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 102000048980 human KRT10 Human genes 0.000 description 1
- 102000045632 human SBSN Human genes 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010014750 prothymosin alpha Proteins 0.000 description 1
- 108700029318 rat female Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010031667 trichohyalin Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Definitions
- the present invention relates to a novel secretory protein expressed in stratified epithelium.
- the epidermis is a typical stratified squamous epithelium that is highly keratinized, and is composed of a basal cell layer, a spiny cell layer, a granular cell layer, and a keratinocyte layer.
- Epidermal cells (keratinocytes) migrate upward from the basal cell layer to the keratinocyte layer. This movement is accompanied by a characteristic morphological change as well as a characteristic keratinocyte diversion.
- the keratinocytes lose their intracellular organelles and become flattened to form the keratinized layer.
- Non-Patent Documents 1 1 3
- keratinocytes in the basement membrane express a basal keratin pair (K5Z K14) that is highly proliferative. Keratinocytes diverge away from the basement membrane and are characterized by changes in keratin expression from K5 / K14 to K1ZK10, an upper basal layer pair (Non-Patent Documents 417).
- keratinocytes also initiate the synthesis of keratinocytes (CE) and precursor proteins such as the cross-linking enzyme transglutaminase (TGase) 1.
- CE keratinocytes
- precursor proteins such as the cross-linking enzyme transglutaminase
- the keratinized membrane (CE) has a highly insoluble structure on the cytoplasmic granule side of the plasma membrane of keratinocytes in the keratinized layer, and also holds various types of protein power cross-linked by TGase 1 (non-patent literature). 8—11).
- CE In terms of epidermal noria function, the components of CE have been well identified, including, for example, cystatin, desmoplakin, empoplakin, elafin, filaggrin and other keratins, involucrin, small proline
- SPRRP rich protein family members
- Non-Patent Document 11 There are rich protein family members (SPRRP) and oral ricklin (Non-Patent Document 11).
- repetin, hornein, and periphilin have been identified as putative CE precursor proteins (Non-patent Documents 12 to 14).
- CE-related proteins are derived from the so-called “Epidermal” on human chromosome lq21 (Non-Patent Documents 15–17) and mouse chromosome 3 (Non-Patent Documents 18 and 19).
- Defferentiation complex (EDC) is encoded by clustered genes.
- EDC Defferentiation complex
- some CE protein genes encoding periplakin, sciellin, empoplin, hornein and periphilin are located in EDC! / ⁇ NA ⁇ (see Non-Patent Documents 20-22, 13, 14) .
- EDC has at least 32 genetic forces that cause the keratinization process, and these genes are classified into three groups based on their structure (see Non-Patent Document 23).
- Non-Patent Document 24 Certain involucrins, oral riculins and SPRRPs each have short tandem repeats in the central region (Non-Patent Document 24).
- Non-Patent Document 25 Used two-dimensional polyacrylamide electrophoresis to clarify the expression of numerous proteins in epidermis and cultured keratinocytes. Reported a partial catalog of secreted proteins in keratinocyte cultures (Non-Patent Document 26).
- Non-Patent Documents 27 and 28 Keratinocyte cDNA libraries randomly sequenced (Non-Patent Documents 27 and 28), Differential Display PCR (Non-Patent Documents 29-34), cDNA Microarray (Non-Patent Documents 35-37), Patent Literatures 38 and 39) and signal sequence traps (Non-Patent Literature 40) have provided the expression profiles of many genes and proteins in keratinocytes.
- the whole skin when used for preparing a cDNA library or a cell lysate, it may be used for keratinocytes, melanocytes, fibroblasts, sebaceous epithelial cells (sebocyte endothelial cells, nerve cells or muscle cells).
- This makes it difficult to analyze the gene expression profile of keratinocytes themselves.
- researchers have used primary cultured keratinocytes, In addition, they are discriminated and suspended culture (raft culture) to form stratified epithelium and obtain information on keratinocytes themselves (Non-Patent Documents 41-45). However, even in this system, it is difficult to obtain information on gene expression in individual layers of the epidermis.
- Non-patent literature 1 Watt FM, “Terminal differentiation of epidermal keratinocytes. J, Curr. Opin. Cell Biol., 1989, Vol. 1, p. 1107-1115.
- Non-Patent Document 2 Eckert RL, "Structure, function and differentiation of the keratinocyte. J, Physiol. Rev. ⁇ 1989, Vol. 69, p. 1316—1346
- Non-Patent Document 3 Eckert RL, Crish JF, Robinson NA, "The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation.”, Physiol. Rev. ⁇ 1997, Vol. 77, p. 397- 424
- Non-Patent Document 4 Fuchs E, Green H, "Changes in keratin gene expression during terminal differentiation of the keratinocyte.”, Cell, 1980, Vol.19, p.1033-1042
- Non-Patent Document 5 Moll R, Franke WW, Vole-Platzer B, Krepler R, "Different keratin polypeptides in epidermis and other epithelia of human skin: a specific cytokeratin of molecular weight 46,000 in epithelia of the pilosebaceous tract and basal cell epitheliomas.”, J Cell Biol, 1982 , Vol.95, p.285— 295
- Non-Patent Document 6 Fuchs E and Byrne C, "The epidermis rising to the surface.”, Curr. Opin. Genetics Dev. ⁇ 1994, Vol. 4, p. 725—736
- Non-Patent Document 7 Fuchs E, ⁇ Keratins and the skin. '', Annu. Rev. Cell Dev. Biol., 1995, Vol. 11, p. 123-153.
- Non-Patent Document 8 Roop, D., "Defects in the barrier.”, Science, 1995, Vol.267, p.474-475.
- Non-Patent Document 9 Ishida-Yamamoto A, lizuka H, "Structural organization of cornified cell envelopes and alterations in inherited skin disorders.”, Exp. Dermatol., 1998, Vol. 7, p. 1-10.
- Non-Patent Document 10 Kalinin A, Marekov LN, Steinert PM, ⁇ Assembly of epidermal cornified cell envelope. '', J. Cell Sci. ⁇ 2001, Vol.114, p.3069-3070
- Non-Patent Document 11 Kalinin AE, Kajava AV, Steinert PM, ⁇ Epithelial barrier lunction: assembly and structural features of the cornified cell envelope. '', BioEssays, 2002, Vol.24, p.789-800
- Patent Document 12 Krieg P, Schuppler M, Koesters R, Mincheva A, Lichter P, and Marks ⁇ Repetin (Rptn), a new member of the "fused gene" subgroup within the S100 gene family encoding a murine epidermal differentiation protein. , Genomics, 1997, Vol. 43, p. 339-348
- Non-Patent Document 13 Makino T, Takaishi M, Morohashi M, Huh N, ⁇ Hornein, a novel profilaggrin- like protein and diffeerntiation- specific marker isolated from mouse skin.J, J Biol. Chem., 2001, Vol. 276, p.47445-47452
- Non-Patent Document l4 Kazerounian S, Aho S, ⁇ Characterization of periphilin, a widespread, highly insoluble nuclear protein and potential constituent of the keratinocyte cornified envelope. '', J. Biol. Chem. ⁇ 2003, Vol. 278, p. .36707-36717
- Non-Patent Document 15 Volz A, Korge BP, Compton JG, Ziegler A, Steinert PM, Mischke D, ⁇ Physical mapping of a functional cluster of epidermal differentiation genes on chromosome lq21. '', Genomics 1993, Vol.18, p.92— 99
- Non-Patent Document 16 Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A, ⁇ Genes encoding structural proteins of epidermal cornification and S100 calcium--binding proteins form a gene complex ("epidermal differentiation complex '') on human chromosome lq21 . ", J. Invest. Dermatol., 1996, Vol. 106, p. 989—992.
- Non-Patent Document 17 Marenholz I, Volz A, Ziegler A, Davies A, Ragoussis I, Korge BP, Mischke D, ⁇ Genetic analysis of the epidermal differentiation complex (EDC) on human chromosome lq21: chromosomal orientation, new markers, and a 6— Mb YAC contig-”, Genomics ⁇ 1996, Vol.37, p.295-302
- Non-Patent Document 18 Rothnagel JA, Longley MA, Bundman DS, Naylor SL, Lalley PA, Jenkins NA, Gilbert DJ, Copeland NG, Roop DR, ⁇ Shi haracterization of the mouse loricrin gene: linkage with profillagerin and the flaky tail and soft coat mutant loci on chromosome 3. '', Genomics, 1994, Vol.23, p.450-456
- Non-Patent Document 19 Song HJ, Poy G, Darwiche N, Lichti U, Kuroki T, Steinert PM, Kartasova T, ⁇ Mouse Sprr2 genes: a clustered family of genes showing differential expression in epithelial tissues. '', Genomics, 1999, Vol.55, p.28-42
- Non-Patent Document 20 Aho S, McLean WHI, Li K, Uitto J, ⁇ cDNA cloning, mRNA expression, and chromosomal mapping of human and mouse periplakin genes. '', Genomics, 1998, Vol. 48, p. 242- 247
- Non-Patent Document 21 Champliaud M, Burgeson RE, Jin W, Baden HP, Olson PF, ⁇ cDNA cloning and characterization of sciellin, a LIM domain protein of the keratinocyte cornified envelope. '', J. Biol. Chem. ⁇ 1998 , Vol.273, p.31547-31554
- Non-Patent Document 22 Maata A, Ruhrberg C, Watt F, ⁇ Structure and regulation of the envoplakin gene.J, J. Biol.Chem. ⁇ 2000, Vol.275, p.19857-19865 ("a” in "Maata” on the left is an umlaut in "a”.)
- Non-Patent Document 23 Marenholtz I, Zirra M, Fischer DF, Backendorf C, Ziegler A, Mischke D, ⁇ Identification of human epidermal differentiation complex
- Non-Patent Document 25 Celis JE, Rasmus sen HH, Gromov P, ⁇ The human keratiocyte two- dimentional gel protein database (update 199 no.mapping components of signal transduction pathways-'', Electrophoresis, 1995, Vol. 16, p. .2177-2240
- Non-Patent Document 2b Katz AB, and Taichman LB, ⁇ A partial catalog of proteins secreted by epidermal keratinocytes in culture. '', J. Invest.Dermatol., 1999, Vol. 112, p. 818-821.
- Patent Document 27 Konishi K, Morishima Y, Ueda E, Kibe Y, Nonomura K, Yamanishi K, Yasuno H, (Cataloging of the genes expressed in human keratinocytes:
- Non-Patent Document 28 Kita H, Okubo K, Matsubara K, ⁇ an expression profile of active genes in cultured human keratinocytes.J, DNA Res., 1996, Vol.3, p.1-7
- Non-Patent Document 29 Frank S, Werner S, ⁇ The human homologue of the yeast CHL1 gene is a novel keratinocyte growth factor-regulated gene. ", J. Biol. Chem. ⁇ 1996 ⁇ Vol.271, p.24337-24340
- Non-Patent Document 30 Frank S, Munz B, Werner S, ⁇
- the human homologue of a bovine nonselenium glutathione peroxidase is a novel keratinocyte growth factor-regulated gene. '', Oncogene, 1997, Vol. 14, p. 915- 921
- Non-Patent Document 31 Munz B, Gerke V, Gillitzer R, Werner S, "Differential expression of the calpain I subunits annexin II and pl l in cultured keratinocytes and during wound repair.”, J. Invest.Dermatol., 1997 , Vol.108, p.307— 312
- Non-Patent Document 32 Rivas MV, Jarvis ED, Morisaki S, Carbonaro H, Gottling AB,
- Non-Patent Document 33 Rutberg SE, Lee EJ, Hansen LH, Glick AB, Yuspa SH, ⁇ Identification of differentially expressed genes in chemically induced skin tumors.J, Mol.Carcinogen., 1997, Vol. 20, p. 80. -98
- Non-Patent Document 34 DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RAS, Nagpal S, ⁇ Identification and characterization of a retinoid- induced class II tumor suppressor / growth regulatory gene. '' Proc. Natl. Acad. Sci. USA. ⁇ 1998, Vol.95, p.14811-14815
- Non-Patent Document 35 Trenkle T, Welsh J, Jung B, Mathieu-Daude F, McClelland M, ⁇ Nonstoichiometric reduced complexity probes for cDNA arrays. '', Nucleic Acids Res., 1998, Vol.26, p.3883- 3891
- Non-Patent Document 36 Cole J, Tsou R, Wallance K, Gibran N, Isik F, ⁇ Early gene expression profile of human skin to injury using high-density cDNA microarrays.J, Wound Repair and Degeneration ⁇ 2001, Vol. 9, p.360—370
- Non-Patent Document 37 Bernard FX, Pedretti N, Rosdy M, Deguercy A, ⁇ Comparison of gene expression profiles in human keratinocyte mono-layer cultures, reconstituted epidermis and normal human skin; transcriptional effects of retinoid treatments in reconstituted human epidermis., Exp. Dermatol., 2002, Vol. 11, p. 59—74 38: Jansen BJH, Van Ruissen F, De Jongh G, Zeeuwen PLJM, Schalkwijk J, ⁇ Serial analysis of gene expression indiiferentiated cultures of human epidermal keratinocytes-'', J. Invest.Dermatol., 2001, Vol. 116, p. .12-22
- Non-Patent Document 39 Ruissen FV, Jansen BJH, dejongh GJ, Zeeuwen PLJM, Schalkwijk J, ⁇ A partial trans criptome of human epidermis '', Genomics, 2002, Vol. 79, p. 671-678.
- Non-Patent Document 40 Bonkobara M, Das A, Takao J, Cruzjr PD, Ariizumi K, ⁇
- Non-Patent Document 41 Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T, ⁇ Living tissue formed in vivo and accepted as skm—equivalemt tissue of full thickness. '', Science, 1981 Cattle, Vol. 211, p. 1052- 1054
- Non-Patent Document 42 Mackenzie IC, Fusenig NE, "Regeneration of organized epithelial structure, J. Invest. Dermatol., 1983, Vol. 81, p.l89s—194s.
- Non-Patent Document 43 Asselineau D, Prunieras M, ⁇ Reconstruction of simplified skin: control of fabrication-'', Br.J.Dermatol., 1984, Vol.111, p.219-222.
- Non-Patent Document 44 Parenteau NL, Nolte CM, Bilbo P, Rosenberg M, Wilkins LM,
- Non-Patent Document 45 Stark HJ, Baur M, Breitkreutz D, Mirancea M, Fusenig NE, ⁇ Organotypic keratinocyte cocultures in defined medium with regular epidermal morphogenesis and differentiation. '', J. Invest.Dermatol., 1999, Vol. 112. , P.681-691
- the present inventors have conducted intensive research to solve the above-mentioned problems.
- the present inventors In order to identify new genes involved in epidermal differentiation, the present inventors have developed a recently established gene screening method called “No-throughput in situ Neubridization System (HT-ISH)” ( Komiya T, Tanigawa Y, Hirohashi S: Anal. Biochem. 254: 23-30, 1997) was used for mouse foot epidermis.
- HT-ISH No-throughput in situ Neubridization System
- This method makes it possible to analyze the pattern of gene expression in individual layers of keratinocytes in the "intact" epidermis without separating the individual cell layers.
- the present inventors By applying this method to mouse plantar epidermal slices, the present inventors have succeeded in identifying one hundred genes showing layer-specific expression in intact epidermis.
- the present inventors identified and characterized two splicing nores, dermokine-a and - ⁇ , of one novel gene, a secretory peptide that is specifically expressed in the spinous layer of the epidermis. did.
- the gene was identified as two other keratinocyte proteins, suprabasin (Park GT, Lim SE, Jang S, Morasso MI: J. Biol. Chem.
- keratinocyte differentiation-related protein (Kdap) (Oomizu S, Sahuc F, Asahina K, Inamatsu M, Matsuzaki T, Sasaki M, Obara M, Yoshizato K: Gene. 256: 19-27, 2000) It was found to be located at the encoding genomic locus. The present inventors have shown that suprabasin and Kdap are also secreted peptides, and that dermokine-aZ-j8, suprabasin and Kdap are mainly expressed in stratified epithelium.
- SSC Stratified epithelium secreted peptides complex
- dermokine-o has the activity of causing keratinocytes to differentiate into stratified epithelial cells by expressing them in keratinocytes.
- the present invention relates to a novel gene involved in epidermal differentiation, and a gene complex containing the gene.
- polypeptide consisting of the amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, or 8, wherein one or more amino acids are substituted, deleted, inserted, and Z or added;
- polynucleotide that hybridizes under stringent conditions to a DNA consisting of the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, and 7, wherein the polynucleotide is expressed on keratinocytes to form an overlap with the keratinocytes.
- a keratinocyte differentiation inducer comprising dermokine-a protein or dermokine- ⁇ protein as an active ingredient
- a method for screening a keratinocyte differentiation inducer comprising the following steps (a)-(c):
- a method for screening a keratinocyte inhibitor comprising the following steps (a) to (c): (a) a step of bringing a test compound into contact with cells expressing dermokine-a protein or dermokine- ⁇ protein
- a method for screening a keratinocyte differentiation inducer comprising the following steps (a)-(c):
- a method for screening a keratinocyte inhibitor comprising the following steps (a)-(c):
- a method for testing a test cell for the strength of cancer cells derived from stratified epithelium comprising the following steps (a) and (b):
- test cell is a cancer cell derived from stratified epithelium when the expression level or the activity is changed as compared to a control
- a method for diagnosing (examining) squamous cell carcinoma or basal cell carcinoma of a subject comprising the following steps (a) and (b): (a) a step of determining whether or not cancer cells derived from stratified epithelium by the method according to (17) for the cell sample prepared by the subject,
- a method for treating a disease caused by reduced keratinocyte differentiation induction comprising a step of administering a keratinocyte differentiation inducer obtained by the screening method according to [13] or [15];
- (23) a method for treating a disease caused by enhanced keratinocyte differentiation, comprising a step of administering a compound selected from the group consisting of the following (a) to (d):
- treatment of a disease caused by enhanced keratinocyte differentiation comprising a step of administering a keratinocyte differentiation inhibitor obtained by the screening method according to [14] or [16].
- FIG. 1 is a diagram and a photograph showing the results of high throughput in situ hybridization (HT-ISH).
- A Evaluation results of the equalized mouse back skin cDNA library are shown.
- the starting library (E0) and the equalized libraries (E1 and E2) were analyzed in duplicate by quantitative real-time PCR analysis. All data were standardized for the internal standard, oral cyclin. Compared to E0, E2 reduced both keratin 14 and keratin 5 cDNAs (rich cDNAs) to about 1/5 each. However, integrin (X-M (rare cDNA) increased to about 42-fold.
- B Photo showing an example of HT-ISH signal.
- CRNA probe power prepared from the equalized cDNA library (E2) 96 Adult mouse foot in the L-format was hybridized to sections of epidermis, cyclophilin A (NM008907) was specifically expressed in the basal and basal layers (a), and Kdap was examined in the suprabasal cell layer.
- prothymosin ⁇ ( ⁇ 008972) (c), diazepam binding inhibitor (BC028874) (d), tubulin j8 -2 chain similar gene (XM130158) (e), lamin A (BC015302) (f), Nuclear distribution C homolog (NM010948) (g), desmoplakin I (XM138593) (h), keratin-related protein 16-5 (NM130857) (i), and nucleoside diphosphate kinase C (AF288691) (j) (K) was detected in the granular layer.Mouth riculin (U09189) mRNA was exclusively (1) No specific signal was detected with the sense probe for each clone (data not shown), the dashed line represents the boundary between epidermis and dermis. Scale bar: 50 ⁇ m.
- FIG. 2-AB A diagram and a photograph showing the identification of dermokine-a and j8.
- A Photograph showing the HT-ISH signal with the SK063F08 probe for a section of an adult mouse foot-epidermis.
- Antisense no signal was detected with the force sense probe (Sense), which gave an intense signal from the spinous layer of the epidermis.
- H + E is a hematoxylin-eosin stained image. Dashed lines represent the boundaries between epidermis and dermis. Scale bar; 50 m.
- B Mouse ESTs having the SK063F08 sequence and their human homologues EST.
- FIG. 2-C is a view showing identification of dermokine-a and j8.
- the amino acid sequences of mouse and human dermokine-a and - ⁇ deduced from each EST of AK003695 / AL832080 and AK081753 / BC035311 are shown.
- the putative signal sequence predicted by the SignalP server is underlined, and the same region between dermokine-a and 13 is boxed. Glycine and serine-rich domains of dermokine- ⁇ are indicated by dashed lines.
- the sequence data of dermokine- ⁇ and dermokine-j8 are registered in GenBank with accession numbers AK003695 and AK081753 for mice and accession numbers AL832080 and BC035311 for humans, respectively!
- FIG. 3-A is a view showing the structure of dermokine-a and - ⁇ genes.
- the exons of the human dermokine-a and -j8 genes on chromosome 19ql31 are shown.
- White and black boxes represent the coding and non-coding regions of the mRNA, respectively, and represent the exon. Putative translation start and stop sites are indicated by ATG and TGA, respectively.
- Exons 2-6 of dermokine- ⁇ were utilized by dermokine-j8 as exons 12-16 and were identical to the COOH-terminal sequence and 3'-noncoding region.
- FIG. 3-B is a view showing the structure of dermokine-a and -j8 genes.
- 1 shows mouse and human loci having genes for suprabasin, demokine- ⁇ / ⁇ ⁇ , and keratinocyte differentiation-related protein (Kdap). Arrows indicate the transfer direction.
- Testis-specific GAPDH testis-specific dalyseraldehyde 3-phosphate dehydrogenase gene
- GPR43 G protein-coupled receptor 43 gene.
- FIG. 4-BC is a photograph showing the result of analyzing the secretion of dermokine- ⁇ / -j8, Kdap and suprabasin.
- B four SEAP (His) fusion proteins in 293 / EBNA-1 cells
- suprabasin lacks its own signal peptide with a (His) C-terminal tag
- SEAP secreted alkaline phosphatase
- fusion proteins were transiently expressed in 293 / EBNA-1 cells.
- the culture medium (10 g in each lane) (Medium) was separated by SDS-PAGE and subjected to immunoblotting with an anti-His antibody.
- the fusion protein secreted into the medium is indicated by an arrowhead. All four fusion proteins were secreted into the medium.
- the culture medium of 293 / EBNA-1 cells was collected, and the fusion protein was purified by TALON Metal Affinity Resin.
- the purified protein (arrow) was degraded by SDS-PAGE, and subsequently stained with Coomassie brilliant blue to analyze the N-terminal amino acid sequence.
- dermokine- ⁇ —SEAP His
- Kdap—SEAP His
- FIG. 5 is a photograph showing the expression pattern of dermokine- ⁇ / ⁇
- the membrane was hybridized with a Kdap-specific probe (Kdap), a suprabasin-specific probe (Suprabasin) and a control GAPDH-specific probe. All genes were highly expressed in the skin, and low in the stomach. Kdap was also detected in the lung.
- Kdap was also detected in the lung.
- B Photographs showing expression patterns of dermokine-a, - ⁇ , Kdap, and suprabasin in epidermis.
- Serial sections of mouse foot ⁇ epidermis were obtained from dermokine-j8 (SK063F08; Dermokine- ⁇ / - ⁇ ), dermokine- ⁇ , ⁇ -holes, Dermo ken e- ⁇ ), Kaap (Kdap; and suprabasin).
- Dermokine-a hybridized with an antisense and sense probe specific to the ZC-terminal region, and showed a section that was hybridized with the sense probe, showing hematoxylin-eosin staining (H + E).
- H + E hematoxylin-eosin staining
- a Z- ⁇ , dermokine- ⁇ and suprabasin-specific hybridization signals were equally detected in the spinous layer of mouse foot-epidermal, but Kdap-specific signals were detected in the suprabasal region of the spinous layer. Signals specific to sections hybridizing with the sense probe were not detected, dashed lines indicate boundaries between epidermis and dermis, scale bar;
- FIG. 6-A Photograph of SSC product. 1 is a photograph showing dermokine- ⁇ / - ⁇ expression during mouse embryonic development. All stage blots (Seegene) of mouse embryos were probed with DIG-labeled SK063F08 cRNA fragment. Dermokine-j8 (arrow) started to be expressed at E15.5. Dermokine- ⁇ (arrowhead) first appeared at E16, its expression increased until E17.5, and then decreased by E18.5. The lower panel is ethidium bromide stained membrane. [6- ⁇ ] is a diagram showing in vitro screening of primary cultured human keratinocytes.
- FIG. 7 is a view showing the effect of Dermokine-o; on keratinocyte differentiation.
- A a graph showing the yield of total RNA from 12 wells.
- pcDNA-human Dermokine- ⁇ -HA was expressed using TransIT LT1 kertinocyte. Only pcDNA3.1 was used as Mock. Extraction of total RNA significantly reduced the amount of total RNA recovered in keratinocytes expressing human Dermokine- ⁇ -HA.
- B is a graph showing the expression of Involucrin. QRT-PCR was performed on involucrin mRNA from total RNA prepared in A. Expression of Dermokine- ⁇ significantly increased involucrin mRNA
- FIG. 8-AB shows a diagram and a photograph showing that an antibody against the SSC protein group was prepared.
- A Diagram of Construct used to create antigen.
- Dermokine-j8-AC lacked the common part of dermokine- ⁇ and dermokine-a, and was used to generate dermokine- ⁇ -specific antibodies.
- ⁇ a photograph showing the protein used for the antigen. 293 / EBNA-1 cells ⁇ ⁇ transiently expressed dermokine- ⁇ , dermokine-j8-AC, Kdap ⁇ Suprabasin fusion protein with SEAP (His)
- the figure is a CBB-stained image.
- FIG. 8-C is a photograph showing that an antibody against the SSC protein group was prepared.
- 4 is a photograph showing an immunoblot using an antiserum against the SSC protein group.
- Dermokine-a, - ⁇ ,- ⁇ Kdap and Suprabasin were transiently expressed in 293 / EBNA-1 cells, respectively, to prepare culture supernatants. After electrophoresis, they were transferred to a nitrocellulose membrane and immunoblotted with antiserum against each protein. The CBB staining image of the culture supernatant is also shown. It was. The antibody against dermokine-a reacts with dermokine- ⁇ - ⁇ C.
- FIG. 9 is a photograph showing the results of analyzing human and mouse dermokine- ⁇ / - ⁇ AC expressed in 293 cells by CBB (Coomassie Brilliant Blue) and immunoblot. The right side of the center is the result of mouse, and the left side is the result of human.
- CBB Clickassie Brilliant Blue
- A is the result of mouse and B is the result of human.
- the present invention relates to a novel secreted protein expressed in the differentiated epidermal layer above the basal layer, and a polynucleotide encoding the protein.
- the proteins of the present invention are believed to be involved in keratinocyte sorting and Z or proliferation.
- the two novel proteins identified in the present invention have been named "dermokine-a” and "dermokine- ⁇ " by the present inventors.
- the nucleotide sequence of the mouse dermokine-a gene is described in SEQ ID NO: 1, and the amino acid sequence of the protein encoded by the gene is described in SEQ ID NO: 2.
- the nucleotide sequence of the mouse dermokine-18 gene is described in SEQ ID NO: 3, and the amino acid sequence of the protein encoded by the gene is described in SEQ ID NO: 4.
- the nucleotide sequence of the human dermokine-a gene is described in SEQ ID NO: 5, and the amino acid sequence of the protein encoded by the gene is described in SEQ ID NO: 6.
- the nucleotide sequence of the human dermokine-18 gene is described in SEQ ID NO: 7, and the amino acid sequence of the protein encoded by the gene is described in SEQ ID NO: 8.
- the present invention first provides a polynucleotide according to any one of the following (a) to (d).
- the above (c) or (d) is the following polynucleotide.
- polypeptide consisting of the amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, or 8, wherein one or more amino acids are substituted, deleted, inserted, and Z or added;
- polynucleotide that hybridizes under stringent conditions to a DNA consisting of the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, and 7, wherein the polynucleotide is expressed on keratinocytes to form an overlap with the keratinocytes.
- a person skilled in the art would determine whether any polypeptide has the ability to have the "activity of causing keratinocytes to differentiate into stratified epithelial cells by being expressed in keratinocytes" as described in (c) or (d) above. Can be appropriately determined.
- a test polypeptide can be introduced into keratinocytes, and the expression can be determined using the expression of a differentiation marker for stratified epithelium, preferably involucrin as an indicator. For example, when the expression of involucrin is increased, the test polypeptide is determined to have “activity of causing keratinocytes to differentiate into stratified epithelial cells by expressing them in keratinocytes”.
- the polynucleotide according to any one of the above ( a ) to (d), which is a gene involved in keratinocyte division and Z or proliferation, and which encodes a secretory protein, is there.
- the dermokine-a protein and dermokine- ⁇ protein in the mouse or human and a variant (variant) of the protein. More specifically, a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 2, 4, 6, or 8, and in the amino acid sequence, one or more amino acids are substituted, deleted, inserted, and The present invention provides a polypeptide consisting of Z or an added amino acid sequence and which is functionally equivalent to the dermokine-a protein or dermokine- ⁇ protein.
- the present invention relates to a polypeptide identified by the present inventors, a polypeptide functionally equivalent to the polypeptide, and a polynucleotide encoding the polypeptide.
- “functionally equivalent” means a polypeptide whose target polypeptide has been identified by the present inventors (for example, a polypeptide having the amino acid sequence power described in SEQ ID NO: 2, 4, 6, or 8). ) Has the same biological function (activity) as! /.
- the biological function (activity) possessed by the polynucleotide of the present invention is, for example, expression in the differentiated epidermal layer in the upper layer of the basal layer or involvement in keratinocyte division and growth or proliferation.
- the activity of inducing keratinocytes can be mentioned.
- Further examples include a function expressed specifically in the stratified epithelium, a function responsible for stratification of the epidermis in vivo in the early stage of mouse development, and the like.
- dermokine-related functions (activities) described in the examples below can be mentioned.
- the present invention provides an amino acid having the amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, or 8, wherein one or more amino acids are substituted, deleted, inserted, and Z or added.
- the present invention also includes polynucleotides that are expressed in, or that encode proteins involved in keratinocyte sorting and Z or proliferation.
- the polynucleotides of the present invention are secretory proteins!
- test polypeptide is a secretory protein
- a test polypeptide is a secretory protein
- it should express a fusion protein tagged with SEAP (secreted alkaline phosphatase) (His).
- SEAP secreted alkaline phosphatase
- a vector is prepared and the vector is transfected into cells.
- immunoblotting with an anti-His antibody it is possible to examine whether or not the test protein is secreted into the cell culture medium. More specifically, it can be carried out by the method described in Examples described later.
- test polypeptide test gene
- test gene test gene
- Northern blotting Western blotting
- Western blotting and so on. It can be appropriately performed by a plotting method, an in situ hybridization method, or the like.
- whether or not the test polypeptide (test gene) is involved in keratinocyte division, Z or proliferation can be determined, for example, under the conditions of high Ca 2+ concentration or high cell density. It can be examined by expression analysis of the test polypeptide (gene). More specifically, it can be confirmed by examining the expression level by qRT-PCR using a stratified epithelial marker. More specifically, it can be appropriately carried out according to the method described in Examples described later.
- polynucleotide of the present invention can be isolated by those skilled in the art by a generally known method. For example, hybridization technology (Southern, EM., J Mol Biol, 1975, 98, 503.) and polymerase chain reaction (PCR) technology (Saiki, RK. Et al, Science, 1985, 230, 1350. Saiki, RK. Et al., Science 1988, 239, 487.).
- hybridization technology Southern, EM., J Mol Biol, 1975, 98, 503.
- PCR polymerase chain reaction
- a polynucleotide consisting of the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, or 7, or a part thereof is used as a probe, and the polynucleotide of any of SEQ ID NOs: 1, 3, 5, or 7 is used as a probe.
- An oligonucleotide which specifically hybridizes or hybridizes to a polynucleotide which also has a nucleotide sequence strength is used as a primer to obtain a polynucleotide having the nucleotide sequence strength described in any one of SEQ ID NOs: 1, 3, 5 and 7 from a desired animal. Isolation of polynucleotides having homology is routine to those skilled in the art.
- polynucleotide that can be isolated by the hybridization technique or the PCR technique and hybridizes with the polynucleotide having the nucleotide sequence described in any of SEQ ID NOs: 1, 3, 5, and 7 is also included in the present invention. Included in polynucleotides. Such polynucleotides include, for example, a gene comprising the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, or 7. And homologs in organisms other than mice and humans.
- the stringent hybridization conditions refer to the conditions of 6M urea, 0.4% SDS, 0.5 ⁇ SSC or the equivalent hybridization condition of stringency.
- 6M urea, 0.4% SDS, 0.1 X SSC it is expected that a polynucleotide with higher homology can be isolated.
- the polynucleotide thus isolated is considered to have high homology at the amino acid level with the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8.
- High homology refers to sequence identity of at least 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more in the entire amino acid sequence.
- the polynucleotide of the present invention includes genomic DNA, cDNA and chemically synthesized DNA. Preparation of genomic DNA and cDNA can be performed by a person skilled in the art by conventional means.
- genomic DNA is extracted from biological force genomic DNA having the polynucleotide of the present invention (for example, the nucleotide sequence of SEQ ID NO: 1, 3, 5, or 7), and a genomic library (for example, a vector such as Plasmids, phages, cosmids, BACs, PACs, etc. can be used), developed, and colony hybridized using a probe prepared based on the polynucleotide of the present invention. Line up Can be prepared.
- a primer specific to the polynucleotide of the present invention for example, SEQ ID NO: 1, 3, 5, or 7
- PCR PCR
- cDNA is synthesized based on mRNA extracted from a biological force having the polynucleotide of the present invention, and the cDNA is inserted into a vector such as ⁇ ZAP to prepare a cDNA library, which is developed and expanded as described above.
- a cDNA library which is developed and expanded as described above.
- it can be prepared by performing colony hybridization or plaque hybridization and by performing PCR.
- the present invention also provides a polynucleotide encoding a protein structurally similar to the protein consisting of the amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, and 8.
- a polynucleotide include a polynucleotide comprising a nucleotide sequence encoding a protein having an amino acid sequence in which one or more amino acids are substituted, deleted, inserted, and Z- or added in the protein.
- the number and location of amino acid mutations in the above proteins are not limited as long as their functions are maintained. The number of mutations will typically be within 10% of all amino acids, preferably within 5% of all amino acids, and more preferably within 1% of all amino acids. More specifically, the number of amino acid mutations is usually within 50 amino acids, preferably within 30 amino acids, more preferably within 10 amino acids, even more preferably within 5 amino acids, and most preferably 3 amino acids. Less than acid.
- the present invention also relates to a polypeptide comprising an amino acid sequence having homology (homology) with the amino acid sequence described in any of SEQ ID NOs: 2, 4, 6, and 8, (Polypeptides).
- the “homology” is not particularly limited as long as the polypeptide has the above-mentioned function (activity), but usually has a homology of 60% or more, preferably 70% or more. % Or more, more preferably 80% or more, even more preferably 85% or more, even more preferably 90% or more, most preferably Have over 95% homology.
- the mutation may not be accompanied by mutation of an amino acid in the protein (degenerate mutation), and such a degenerate mutant polynucleotide is also included in the present invention.
- the present invention also provides fragments of the polypeptide of the present invention.
- a fragment is a polypeptide having an amino acid sequence that is not entirely identical to a portion of the amino acid sequence of the polypeptide of the present invention.
- the polypeptide fragment of the present invention is usually a polypeptide fragment having a sequence of 8 amino acid residues or more, preferably 12 amino acid residues or more (for example, 15 amino acid residues or more).
- Suitable fragments include, for example, a deletion of a series of residues including the amino terminus or a series of residues including the carboxyl terminus, or a combination of a series of residues including the amino terminus and a series of residues including the carboxyl terminus.
- truncation polypeptides having an amino acid sequence with truncated residues deleted.
- fragments characterized by structural or functional properties such as those that contain variable regions, surface forming regions, substrate binding regions, and high antigen index regions.
- Variants of the specified sequences and fragments also form part of the invention.
- Preferred variants are those that involve substitution of conservative amino acids. That is, a residue is substituted with another residue of similar properties.
- Typical such substitutions are, for example, between Ala, Val, Leu and lie, between Ser and Thr, between the acidic residues Asp and Glu, between Asn and Gin, between the basic residues Lys and Arg, Or occurs between the aromatic residues Phe and Tyr.
- the amino acid to be substituted is preferably an amino acid having properties similar to the amino acid before substitution from the viewpoint of maintaining the function of the protein.
- Ala, Val, Leu, Ile, Pro, Met, Phe, and Trp are all classified as non-polar amino acids, and are considered to have similar properties to each other.
- examples of the non-charger include Gly, Ser, Thr, Cys, Tyr, Asn, and Gin.
- acidic amino acids include Asp and Glu
- basic amino acids include Lys, Arg, and His. Therefore, the type of amino acid to be modified in the present invention is not particularly limited, but the amino acids before and after modification are separated into properties similar to those described above. Preferably, the amino acids are similar to each other.
- polypeptide encoded by the polynucleotide of the present invention is also included in the present invention.
- the present invention provides a vector into which the polynucleotide of the present invention has been inserted, the polynucleotide of the present invention or a host cell carrying the vector, and a method for producing the polypeptide of the present invention using the host cell. .
- the vector of the present invention is not particularly limited as long as it can stably maintain the inserted DNA.
- a pBluescript vector manufactured by Stratagene
- an expression vector is particularly useful.
- the expression vector is not particularly limited as long as it expresses the polypeptide in a test tube, in Escherichia coli, in cultured cells, or in an individual organism. Examples of the expression vector include a pBEST vector (manufactured by Promega) for expression in a test tube.
- pET vector manufactured by Invitrogen
- PME18S-FL3 vector GeneBank Accession No. AB009864
- PME18S vector Mol Cell Biol. 8: 466-472 (1988)
- Insertion of the DNA of the present invention into a vector can be performed by a conventional method, for example, by a ligase reaction using a restriction enzyme site (Current protocols in Molecular Biology edit.Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11.4—11.11).
- the host cell into which the vector of the present invention is introduced is not particularly limited, and various host cells may be used depending on the purpose.
- Cells for expressing the polypeptide include, for example, bacterial cells (eg, Streptococcus, Staphylococcus, Escherichia coli, Streptomyces, Bacillus subtilis), fungal cells (eg, yeast, Aspergillus), insect cells (eg, Drosophila S2) , Spodoptera SF9), animal cells (eg, CHO, COS, HeLa, C127, 3T3, BHK, HEK293, Bowes melanoma cells) and plant cells.
- Vectors can be introduced into host cells by, for example, calcium phosphate precipitation, electropulse perforation (Current protocols in
- the medium is recovered.
- the polypeptide of the present invention is produced intracellularly, the cell is first lysed and then the polypeptide is recovered.
- Recombinant cell cultures also have the ability to recover and purify the polypeptides of the present invention by precipitation with ammonium sulfate or ethanol, acid extraction, ion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography.
- Known methods including chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography can be used.
- the present inventors also concluded that the dermokine-a gene and the dermokine- ⁇ gene of the present invention were located between the keratinocyte-digestion-related protein (Kdap) -encoding gene and the suprabasin (spravacin) gene. I found out. In addition, they discovered for the first time that these four genes are secreted proteins and are gene complexes (gene clusters) expressed at the onset of stratification. That is, the above four genes are under common gene expression regulation, and constitute a gene complex. The present inventors named the gene complex SSC.
- the present invention relates to a gene complex characterized by being under common gene expression regulation, comprising: (1) a Kdap gene, (2) a dermokine- ⁇ gene, (3) a dermokine-j8 gene, and (4) To provide a gene complex involved in the division or growth of keratinocytes composed of each gene of the uprabasin gene.
- the gene complex of the present invention is located on chromosome 7 in mice and on chromosome 19 in humans, as shown in Fig. 3, for example. Those skilled in the art can use the information shown in FIG. 3 to obtain information on the exact position and sequence of the gene complex of the present invention by appropriately using public databases, commercially available analysis tools, and the like. It is possible to obtain it.
- the gene complex of the present invention is preferably a genomic DNA fragment containing the gene of (1) or (4) above, and desirably contains a common expression control region of the gene.
- the genomic DNA fragment is preferably an isolated and purified DNA fragment.
- the DNA fragment is preferably derived from a mouse or human.
- the genomic DNA fragment of the present invention is not particularly limited! /, But is a DNA fragment having a length of about 40 kbp (approximately).
- the present invention relates to the polynucleotide of the present invention (eg, the polynucleotide having the nucleotide sequence of any of SEQ ID NOs: 1, 3, 5, and 7, or a complementary strand thereof). Both nucleotides have a nucleotide length of 15 nucleotides.
- complementary strand refers to one strand of a double-stranded nucleic acid that has the base pair force of A: T (U for RNA) and G: C.
- ⁇ complementary '' is not limited to a case where the sequence is completely complementary to at least 15 contiguous nucleotide regions, and is at least 70%, preferably at least 80%, more preferably 90%, and still more preferably 95%. It is only necessary to have the above homology on the base sequence.
- the algorithm for determining homology should use the one described herein.
- Such a nucleotide can be used as a probe for detecting and isolating the polynucleotide of the present invention, and as a primer for amplifying the nucleotide of the present invention. When used as a primer, it usually has a chain length of 15-100 nucleotides, preferably 15-35 nucleotides.
- a polynucleotide having a chain length of at least 15 nucleotides, preferably at least 30 nucleotides, containing at least a part or the entire sequence of the DNA of the present invention is used.
- Such a polynucleotide preferably hybridizes specifically to a polynucleotide encoding the polypeptide of the present invention.
- “Specifically hybridizes” refers to a polynucleotide of the present invention (eg, SEQ ID NO: 1, 3, 5, or 7) under ordinary hybridization conditions, preferably under stringent conditions. DNA that hybridizes and encodes another polypeptide means that it does not hybridize.
- the above polynucleotides include polynucleotides that suppress the expression of a gene encoding the polypeptide of the present invention.
- Such polynucleotides include antisense polynucleotides (antisense DNA / RNA; genes encoding the polypeptides of the present invention).
- Ribozyme RNA encoding ribozyme activity that specifically cleaves a transcript of a gene encoding the polypeptide of the present invention
- DNA nucleic acids having an RNAi effect.
- the action of the antisense polynucleotide to suppress the expression of the target gene includes the following multiple factors. In other words, inhibition of transcription initiation by triplex formation, suppression of transcription by hybridization with a site where a local open loop structure was formed by RNA polymerase, inhibition of transcription by hybridization with RNA that is undergoing synthesis, and inhibition of intron.
- the antisense nucleic acid (polynucleotide) used in the present invention may suppress the expression of a target gene by any of the above actions.
- designing an antisense sequence complementary to the untranslated region near the 5 'end of the mRNA of a gene is considered to be effective in inhibiting translation of the gene.
- sequences complementary to the coding region or the 3 'untranslated region may also be used.
- the polynucleotide containing the antisense sequence of the sequence of the untranslated region as well as the translated region of the gene is also included in the antisense polynucleotide used in the present invention.
- the antisense polynucleotide to be used is ligated downstream of an appropriate promoter, and preferably a sequence containing a transcription termination signal is ligated on the 3 'side.
- An antisense polynucleotide sequence is a sequence that is complementary to a target gene or a portion thereof. It is preferable that they are not completely complementary as long as they can effectively inhibit gene expression.
- the transcribed RNA preferably has at least 90%, most preferably at least 95% complementarity to the transcript of the target gene.
- the antisense polynucleotide In order to effectively inhibit the expression of a target gene using an antisense sequence, the antisense polynucleotide must have at least 15 nucleotides or more, preferably 100 nucleotides, and more preferably 500 nucleotides or more to cause an antisense effect. And usually has a chain length of no more than 3000 nucleotides, preferably no more than 2000 nucleotides.
- the antisense polynucleotide can be obtained, for example, based on the sequence information of a polynucleotide (eg, SEQ ID NO: 1, 3, 5, or 7) encoding the polypeptide of the present invention based on the phosphorothione method (Stein, 1988 Physicochemicai properties of phosphorothioate
- Suppression of the expression of an endogenous gene can also be performed using a nucleic acid (polynucleotide) encoding a ribozyme.
- a ribozyme is an RNA molecule having catalytic activity. There are ribozymes with various activities. Among them, research on ribozymes as enzymes that cleave RNA has made it possible to design ribozymes for site-specific cleavage of RNA.
- Some ribozymes have an active domain of about 40 nucleotides called the hammerhead type or the hapin type, some of which are more than 400 nucleotides in size, such as the group I intron type and the M1 RNA contained in RNaseP ( Makoto Koizumi and Eiko Otsuka, (1990) Protein nucleic acid enzyme, 35: 2191).
- the self-cleaving domain of the hammerhead ribozyme cleaves the 3 ′ side of C13 of G13U14C15, but it is important for the activity that U14 forms a base pair with A at position 9; Has been shown to be cleaved by A or U in addition to C (M. Koizumi et al., (1988) FEBS Lett. 228: 225).
- ribozyme substrate-binding site is designed to be complementary to the RNA sequence near the target site, it is possible to create a restriction-enzymatic RNA-cleaving ribozyme that recognizes the UC, UU, or UA sequence in the target RNA (M.Koizumi et al., (1988) FEBS Lett. 239: 285, Makoto Koizumi and Eiko Otsuka, (1990) Protein nucleic acid enzyme, 35: 2191,
- Hairpin ribozymes are also useful for the purpose of the present invention. Hairpin-type ribozymes are found, for example, in the minus strand of satellite RNA of tobacco ring spotinoles (JMBuzayan Nature 323: 349, 1986). It has been shown that this ribozyme can also be designed to cause target-specific RNA cleavage (Y. Kikuchi and N. Sasaki (1992) Nucleic Acids Res. 19: 6751, Kikuchi Hiroshi, (1992) Chemistry and Biology 30). : 112).
- the preferred siRNA of the present invention ! /, as an embodiment, dermokine-a or
- Double-stranded RNA having an RNAi (RNA interference) effect on the dermokine- ⁇ gene can be mentioned. More specifically, a double-stranded RNA (siRNA) having a sense RNA and an antisense RNA with respect to the partial sequence of the base sequence described in any of SEQ ID NOs: 1, 3, 5, and 7 can be mentioned.
- the enzyme called DICER comes into contact with double-stranded RNA, and the double-stranded RNA is converted into small interfering RNA or siRNA. It is thought to be broken down into smaller pieces called.
- the double-stranded RNA having the RNAi effect in the present invention also includes the double-stranded RNA before being degraded by DICER. In other words, even a long-chain RNA that does not have the RNAi effect if it has the same length is expected to be degraded into siRNA having the RNAi effect in cells, so that the present invention
- the length of double-stranded RNA is not particularly limited
- RNA corresponding to the full-length or almost full-length region of the mRNA of the dermokine gene of the present invention can be degraded by, for example, DICER in advance, and the degradation product can be appropriately used.
- This degradation product is expected to include a double-stranded RNA molecule (siRNA) having an RNAi effect.
- siRNA double-stranded RNA molecule
- the region on the mRNA expected to have the RNAi effect does not have to be particularly selected. That is, the region on the mRNA of the dermokine gene of the present invention having the RNAi effect does not necessarily have to be precisely defined! /.
- the present invention also includes a molecule having a structure in which one end of the RNA molecule is closed, for example, siRNA (shRNA) having a hairpin structure. That is, a single-stranded RNA molecule capable of forming a double-stranded RNA structure in the molecule is also included in the present invention.
- siRNA siRNA
- the above "double-stranded RNA that can be suppressed by the RNAi effect" of the present invention is It can be appropriately prepared based on the base sequence of the dermokine gene of the present invention, which is a target of double-stranded RNA.
- the double-stranded RNA of the present invention can be prepared based on the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, and 7. That is, based on the base sequence described in any one of SEQ ID NOs: 1, 3, 5, and 7, an arbitrary continuous RNA region of mRNA which is a transcript of the sequence is selected and corresponds to this region.
- RNA sequence having a stronger RNAi effect from an mRNA sequence which is a transcript of the sequence by a known method.
- one strand for example, the nucleotide sequence described in any one of SEQ ID NOs: 1, 3, 5, and 7
- those skilled in the art can easily understand the other strand (complementary sequence). Chain) can be known.
- Those skilled in the art can appropriately produce siRNA using a commercially available nucleic acid synthesizer. For synthesis of desired RNA, a general synthesis service can be used.
- a DNA (vector) capable of expressing the above RNA of the present invention is also a DNA of the present invention.
- a DNA (vector) capable of expressing the above-described double-stranded RNA of the present invention includes a DNA encoding one strand of the double-stranded RNA and a DNA encoding the other strand of the double-stranded RNA, respectively. DNA having a structure linked to a promoter so that it can be expressed.
- the above-mentioned DNA of the present invention can be appropriately prepared by those skilled in the art by general genetic engineering techniques. More specifically, the expression vector of the present invention can be prepared by appropriately inserting a DNA encoding the RNA of the present invention into various known expression vectors.
- a viral vector such as a retrovirus vector, an adenovirus vector, and an adeno-associated virus vector
- a non-viral vector such as ribosome or ribosome.
- the present invention provides an antibody that binds to the polypeptide of the present invention.
- antibody Includes polyclonal and monoclonal antibodies, chimeric antibodies, single-chain antibodies, humanized antibodies, as well as Fab fragments containing Fab or the products of other immunoglobulin expression libraries.
- the polypeptide of the present invention or a fragment or analog thereof, or a cell expressing the same, can also be used as an immunogen for producing an antibody that binds to the polypeptide of the present invention.
- the antibodies are preferably immunospecific for a polypeptide of the invention. "Immunospecific" means that the antibody has a substantially higher affinity for the polypeptide of the invention than for its affinity for other polypeptides.
- Antibodies that bind to the polypeptide of the present invention can be prepared by methods known to those skilled in the art.
- a polyclonal antibody can be obtained, for example, as follows.
- the polypeptide of the present invention or its fusion protein with GST is immunized to small animals such as egrets to obtain serum.
- This is prepared by, for example, purification using ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, an affinity column to which the polypeptide of the present invention is coupled, and the like.
- a monoclonal antibody for example, a small animal such as a mouse is immunized with the polypeptide of the present invention, a spleen is excised from the mouse, and the spleen is crushed to separate cells, and mouse myeloma cells and polyethylene glycol are used. And a clone that produces an antibody that binds to the polypeptide of the present invention is selected from the resulting fused cells (hybridomas).
- the obtained no and ibridomas are transplanted intraperitoneally into the mouse, ascites is collected from the mouse, and the obtained monoclonal antibody is subjected to, for example, ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography. Alternatively, it can be prepared by purifying with an affinity column or the like to which the polypeptide of the present invention has been coupled.
- the antibody of the present invention can be used for isolation, identification, and purification of the polypeptide of the present invention and cells expressing the same.
- the present inventors have succeeded in actually producing antibodies (polyclonal antibodies) against the human dermokine- ⁇ , -j8, Kdap, and Suprabasin proteins of the present invention.
- an antibody against human dermokine- ⁇ , -j8, Kdap, or Suprabasin shown in Examples described later can be mentioned.
- dermokine knockout mice can be produced based on the findings found by the present inventors. The knockout animal (non-human animal) is very useful for studying the physiological role of SSC.
- the present invention relates to an animal (non-human animal) in which the expression of the gene of the present invention (for example, dermokine- ⁇ / ⁇ ⁇ ) is artificially suppressed.
- gene expression is artificially suppressed generally means that one or both of a gene pair has a gene mutation such as insertion, deletion, or substitution of a nucleotide and so on. Is suppressed! A case where the function as a normal protein is reduced or lost! /, Or a mutant protein is expressed! /, Is also included in the “suppression of gene expression”.
- suppression includes the case where only the expression of one gene of the gene pair of the gene is suppressed when the expression of the gene is completely suppressed.
- the target of genetic modification is usually an animal other than a human, preferably a rodent such as a mouse, a rat, a nose, a muster, a rabbit, and particularly a mouse. Is preferred.
- ES cells to be subjected to gene modification are also preferably derived from mice, particularly those derived from rodents.
- the “knockout animal” generally referred to is also included in the genetically modified animal of the present invention.
- the means for artificially suppressing gene expression includes deletion of the entire gene or a part thereof.
- the method include a method of deleting a gene and a method of deleting all or a part of the expression control region of a gene, and preferably a method of inactivating a gene by inserting a foreign gene into one or both of a gene pair.
- the genetically modified animal is characterized in that a foreign gene is inserted into one or both of a gene pair.
- the genetically modified animal of the present invention can be produced by those skilled in the art by generally known genetic engineering techniques.
- a genetically modified mouse can be prepared as follows. First, DNA containing the etason portion of the gene of the present invention (for example, dermokine- ⁇ / ⁇ ⁇ ) is isolated from a mouse, and an appropriate marker gene is inserted into this DNA fragment to obtain a DNA fragment. -Construct a targeting vector. This targeting vector is introduced into a mouse ES cell line by the electo-portion method or the like, and a cell line in which homologous recombination has occurred is selected. As a marker gene to be inserted, an antibiotic resistance gene such as a neomycin resistance gene is preferable.
- a cell line in which homologous recombination has occurred can be selected only by culturing in a medium containing the antibiotic.
- a homologous recombinant was assayed by PCR and Southern blotting. It is advantageous to obtain a cell line in which one of the gene pairs of the gene of the present invention has been inactivated.
- chimera production may be performed using a plurality of clones in addition to the homologous recombination site because unknown gene disruption may be caused by gene insertion. Preferred ⁇ .
- the obtained ES cell line is injected into mouse blastoderm to obtain a chimeric mouse.
- a mouse in which one of the gene pairs of the gene of the present invention is inactivated can be obtained.
- a mouse in which both of the gene pair of the gene of the present invention are inactivated can be obtained.
- Gene modification can also be performed in animals other than mice in which ES cells have been established by the same method.
- an ES cell line in which both of the gene pair of the gene of the present invention are inactivated can be obtained by the following method. That is, by culturing an ES cell strain in which one of the gene pairs has been inactivated, in a medium containing a high concentration of an antibiotic, the cell line in which the other of the gene pairs has been inactivated, that is, the present invention, An ES cell line in which both gene pairs of genes have been inactivated can be obtained. Alternatively, it can be prepared by selecting an ES cell line in which one of the gene pairs has been inactivated, introducing a targeting vector again into this cell line, and selecting a cell line in which homologous recombination has occurred.
- the marker gene to be inserted into the targeting vector is preferably different from the above-mentioned marker gene.
- the present invention also provides a cell line established from the genetically modified non-human animal of the present invention.
- Known methods can be used to establish the cell line derived from the genetically modified animal of the present invention.
- the method of primary culture of fetal cells can be used. (Shinsei Kagaku Kenkyusho, Vol. 18, pp. 125-129, Tokyo Kagaku Doujin and Mouse Embryo Operation Manual, pp. 262-264, Modern Press).
- the genetically modified animal of the present invention a cell line established from the animal, and an ES cell line can be used for detailed analysis of the function of the gene of the present invention. Furthermore, the genetically modified animal of the present invention can be used for a method for screening a compound that substitutes for the function of the protein of the present invention.
- the polypeptide (protein) of the present invention is expected to have a keratinocyte differentiation-inducing action. Therefore, the present invention relates to a keratinocyte differentiation inducer (hereinafter, sometimes referred to as a “differentiation inducer”) containing the polypeptide (protein) of the present invention as an active ingredient.
- a keratinocyte differentiation inducer hereinafter, sometimes referred to as a “differentiation inducer”
- the present invention provides a keratinocyte differentiation inducer comprising a dermokine-a protein or a dermokine- ⁇ protein as an active ingredient.
- the dermokine- ⁇ protein includes, for example, the polypeptide described in SEQ ID NO: 2 or 6.
- the dermokine-j8 protein may be, for example, the polypeptide of SEQ ID NO: 4 or 8.
- the present invention also includes a DNA encoding the above-mentioned polypeptide, which is a component of the present invention inducer.
- the present invention also relates to an agent for inducing keratinocyte differentiation, comprising a substance for activating expression of SSC or dermokine- ⁇ / ⁇ protein.
- the “protein expression activity” is a substance (protein) that significantly activates (increases) protein expression.
- the “activation of expression” of the present invention includes the activation of transcription of a gene encoding the protein and the activation of translation of ⁇ or the transcription product of the gene.
- the SSC or dermokine- ⁇ / ⁇ protein expression activator of the present invention includes, for example, a gene that binds to the transcriptional regulatory region (eg, promoter region) of the SSC or dermokine-aZjS gene, Substances that promote the transcription of transcription (such as transcription activation factor) It comes out.
- a gene that binds to the transcriptional regulatory region (eg, promoter region) of the SSC or dermokine-aZjS gene Substances that promote the transcription of transcription (such as transcription activation factor) It comes out.
- the expression activity of SSC or dermokine- ⁇ / ⁇ protein can be measured by methods known to those skilled in the art, for example, RT-PCR, Northern plotting, Western plotting. It can be easily implemented by a method or the like.
- dermokine-a protein or dermokine- ⁇ protein are collectively referred to as “dermokine- ⁇ / ⁇ protein (gene)”.
- the substance (compound) that suppresses the expression or function of (sometimes) is expected to have a keratinocyte differentiation inhibitory action.
- the present invention relates to a keratinocyte inhibitor (hereinafter referred to as a “differentiation inhibitor”) containing a dermokine- ⁇ protein or dermokine- ⁇ protein expression or function inhibitory substance (compound) as an active ingredient. May be written).
- the "expression inhibitor” according to the present invention which significantly lowers the expression of a protein, is a substance (a conjugate) that completely suppresses the expression.
- the “inhibition of expression” of the present invention includes inhibition of transcription of a gene encoding the protein and inhibition of translation of ⁇ or the transcription product of the gene.
- a preferred embodiment of the above-mentioned disulfide inhibitor is a drug containing, as an active ingredient, a compound selected from the group consisting of the following (a) to (d).
- RNAi RNA interference
- RNAi is a method for introducing double-stranded RNA having a sequence identical or similar to the target gene sequence into cells. When inserted, it refers to a phenomenon in which the expression of both the introduced foreign gene and the target endogenous gene is inhibited.
- RNAi RNA used for RNAi need not be completely identical to the dermokine- ⁇ gene or a partial region of the gene, but preferably has complete homology.
- Examples of the dermokine- ⁇ / ⁇ protein function inhibitor include the above antibodies of the present invention, for example, an antibody that binds to dermokine- ⁇ / ⁇ protein (an antibody that recognizes dermokine- ⁇ / ⁇ protein; dermokine- ⁇ / ⁇ protein antibody).
- the antibody inhibits the function of the dermokine-aZ ⁇ protein by binding to the dermokine- ⁇ / ⁇ protein, and as a result, is expected to induce keratinocyte division.
- the antibody of the present invention does not bind to proteins other than dermokine-aZjS and specifically binds to dermokine- ⁇ / ⁇ protein (recognizes dermokine-a / ⁇ protein).
- it is an antibody.
- the antibody that binds to the dermokine- ⁇ / ⁇ protein of the present invention may be used, for example, for the purpose of suppressing keratinocyte differentiation.
- a human antibody or a humanized antibody is preferable in order to reduce immunogenicity.
- the keratinocyte differentiation-inducing agent of the present invention is expected to be a therapeutic agent for diseases caused by abnormal keratinocyte differentiation (reduced differentiation).
- diseases caused by abnormal keratinocyte differentiation include psoriasis vulgaris with parakeratosis, actinic keratosis and the like.
- the keratinocyte disulfide inhibitor of the present invention is expected to be a therapeutic agent for a disease caused by enhanced keratinocyte dilation.
- the disease include ichthyosis vulgaris with hyperkeratosis, sex-related ichthyosis vulgaris, wart vulgaris, lichen amyloid and lichen planus with thickening of the granular layer, vesicular congenital ichthyosis-like red Skin diseases such as dermatoses.
- the keratinocyte migration inducer or the keratinocyte migration inhibitor of the present invention may be a physiologically acceptable carrier.
- Oral or parenteral as a pharmaceutical composition by mixing with the body, excipients, or diluents, etc. Can be administered.
- Oral preparations can be in the form of granules, powders, tablets, capsules, solvents, emulsions, suspensions and the like.
- a dosage form such as an injection, a drip, an external preparation, or a suppository can be selected. Injections include subcutaneous injections, intramuscular injections, and intraperitoneal injections.
- the topical drug may be a nasal agent or an ointment. Formulation techniques for preparing the above-mentioned dosage form so as to contain the differentiation inducer of the present invention as a main component are known.
- a tablet for oral administration can be produced by adding an excipient, a disintegrant, a binder, a lubricant and the like to the drug of the present invention, mixing and compression-shaping.
- an excipient lactose, starch, mannitol and the like are generally used.
- disintegrant calcium carbonate, carboxymethylcellulose calcium and the like are generally used. Gum arabic, carboxymethylcellulose, or polyvinylpyrrolidone is used as the binder.
- Known lubricants include talc magnesium stearate and the like.
- the tablet containing the drug of the present invention can be coated with a known coating for masking and enteric-coated preparations.
- Ethyl cellulose, polyoxyethylene glycol, or the like can be used as the coating agent.
- An injection can be obtained by dissolving the agent of the present invention as a main component together with a suitable dispersant, dissolving or dispersing in a dispersion medium.
- a suitable dispersant dissolving or dispersing in a dispersion medium.
- any of an aqueous solvent and an oily solvent can be used.
- an aqueous solvent distilled water, physiological saline, Ringer's solution, or the like is used as a dispersion medium.
- an oily solvent various vegetable oils such as propylene glycol are used as a dispersion medium.
- a preservative such as paraben can be added as necessary.
- known tonicity agents such as sodium salt and glucose can be added to the injection.
- a soothing agent such as Shiridani Benzalko-Pam Hydrochloride Proforce In can be added.
- the drug of the present invention can be used as an external preparation by preparing a solid, liquid, or semi-solid composition.
- a solid or liquid composition an external preparation can be prepared by using the same composition as described above.
- the semi-solid composition can be prepared by adding a thickener to an appropriate solvent, if necessary.
- Water, ethyl alcohol, polyethylene glycol, or the like can be used as the solvent.
- Thickeners include general For example, bentonite, polybutyl alcohol, acrylic acid, methacrylic acid, or polybutylpyrrolidone is used.
- a preservative such as Shiojiri Benzalco-Pum can be added.
- suppositories can be prepared by combining an oily base such as cocoa butter or an aqueous gel base such as a cellulose derivative as a carrier.
- the drug of the present invention is administered to mammals including humans in a required amount within a safe dose range.
- the dose of the drug of the present invention can be finally determined appropriately by the judgment of a doctor or veterinarian in consideration of the type of the dosage form, the administration method, the age and weight of the patient, the symptoms of the patient, and the like.
- the drug of the present invention also includes, for example, dry skin, dandruff, acne, keratosis, eczema, skin peeling, pruritus,
- dry skin, dandruff, acne, keratosis, eczema, skin peeling, pruritus For abnormal biological symptoms or injuries of the epidermis such as senile spots, moles, melasma, wrinkles, warts, skin spots, hyperpigmented skin, hyperkeratotic skin, inflammatory skin, age-related skin changes, etc.
- the drug of the present invention is generally used for humans, but can also be used for skin diseases such as dogs and cats.
- the present invention also provides a method for screening a keratinocyte differentiation inducer (a compound having a differentiation induction effect).
- a preferred embodiment of the screening method of the present invention is a method using the expression level or activity of dermokine- ⁇ / ⁇ protein as an index. That is, a compound that increases the expression or activity of the dermokine- ⁇ / ⁇ protein is expected to have a keratinocyte differentiation-inducing action.
- test compound is brought into contact with cells expressing dermokine-a and Z or j8 protein (gene).
- the “cell” used in the present method is not particularly limited, but is preferably a human-derived cell.
- “Cells that express dermokine- ⁇ / ⁇ protein” include cells that express endogenous dermokine-a / ⁇ protein, or cells into which exogenous dermokine- ⁇ / ⁇ gene is introduced, and the gene is expressed. You can use the cells that do.
- Cells expressing the exogenous dermokine- ⁇ gene are usually expressed with the dermokine- ⁇ / ⁇ gene inserted. It can be prepared by introducing a vector into a host cell.
- the expression vector can be prepared by general genetic engineering techniques.
- test compound to be used in the screening method of the present invention is not particularly limited.
- single compounds such as natural compounds, organic compounds, inorganic compounds, proteins, and peptides, as well as compound libraries, expression products of gene libraries, cell extracts, cell culture supernatants, fermentation microorganism products, and marine products
- compound libraries include, but are not limited to, biological extracts and plant extracts.
- test compounds can be appropriately labeled and used as necessary.
- the label include a radiolabel, a fluorescent label and the like.
- the "contact" of a test compound with cells expressing the dermokine- ⁇ / ⁇ gene is usually performed by adding the test compound to a culture solution of cells expressing the dermokine- ⁇ / ⁇ gene. It does, but is not limited to this method.
- “contact” can be performed by introducing a DNA vector expressing the protein into the cell.
- the expression amount or activity of dermokine- ⁇ / ⁇ protein in cells expressing dermokine- ⁇ / ⁇ protein is measured in the following manner.
- the measurement of the expression level can be easily performed by those skilled in the art, and can be appropriately performed by a general method, for example, the Northern plot method, the Westerlot method and the like.
- "expression” means either transcription of a gene encoding a protein (production of mRNA) or translation of a transcription product of the gene.
- the above-mentioned screening method is performed using the activity of dermokine- ⁇ / ⁇ protein as an index, the above-mentioned function (activity) of dermokine- ⁇ / ⁇ protein, for example, the distribution of keratinocytes of dermokine- ⁇ / ⁇ protein.
- the dani induction activity can be used as an index.
- the measurement of the activity of the dermokine-aZjS protein can be appropriately performed by those skilled in the art by a known method.
- the above-mentioned “activity” is preferably the above-mentioned “dermokine-a”. / Expression of ⁇ protein in keratinocytes to cause the keratinocytes to differentiate into stratified epithelial cells ”.
- test compound is not brought into contact with
- a compound that increases the expression level or activity of the dermokine- ⁇ / ⁇ protein is selected.
- the compound obtained by the above screening method is expected to be, for example, a therapeutic agent for a disease caused by abnormal keratinocyte differentiation.
- the present invention also provides a method for screening a keratinocyte differentiation inhibitor (a compound having a differentiation-inducing action).
- a preferred embodiment of the screening method of the present invention is a method using the expression level or activity of dermokine- ⁇ / ⁇ protein as an index. That is, a compound that decreases (inhibits) the expression or activity of the dermokine- ⁇ / ⁇ protein is expected to have a keratinocyte binding inhibitory action.
- the above method of the present invention can be appropriately carried out according to the above-described method for screening for a differentiation inducer. That is, in the above method of the present invention, first, a test compound is contacted with cells expressing dermokine-a and Z or j8 protein (gene). Next, a compound that reduces the expression level or activity of the dermokine- ⁇ / ⁇ 8 protein compared to the case where the test compound is not contacted is selected.
- the compound obtained by the above screening method is expected to be, for example, a therapeutic agent for a disease caused by enhanced keratinocyte differentiation.
- a preferred embodiment of the above-described screening method of the present invention is a screening method using the above-mentioned "activity of expressing dermokine-a / ⁇ protein in keratinocytes to differentiate the keratinocytes into stratified epithelial cells" as an index. .
- the present invention relates to a method for screening a keratinocyte differentiation inducer, comprising the following steps (a) to (c).
- the present invention also provides a method for screening a keratinocyte migration inhibitor, comprising the following steps (a) to (c).
- Another embodiment of the present invention is a method for screening for a keratinocyte differentiation inducer, comprising the following steps (a) to (c).
- Still another embodiment of the present invention relates to a method for screening a keratinocyte inhibitor, comprising the following steps (a) to (c).
- Cells expressing the dermokine- ⁇ / - ⁇ protein in the above step (a) are allowed as long as they can be cultured together with keratinocytes, and may be keratinocytes themselves. Keratinocytes are preferred. Cells expressing the dermokine- ⁇ / - ⁇ protein are usually ready for expression of the DNA encoding the dermokine- ⁇ / ⁇ protein. It can be produced by introducing the retained vector (dermokine- ⁇ / ⁇ expression vector) into keratinocytes.
- the "activity of expressing dermokine- ⁇ / ⁇ protein in keratinocytes to divide the keratinocytes into stratified epithelial cells" in step (b) is, for example, a differentiation marker of stratified epithelium, preferably Can be measured as appropriate using the expression of involucrin as an index.
- a compound that increases the expression of involucrin is determined to have a keratinocyte differentiation-inducing effect, and a compound that decreases the expression of involucrin is determined to have a keratinocyte-digesting inhibitory effect.
- the dermokine- ⁇ / ⁇ protein of the present invention is expressed in stratified epithelium, it is expected that, for example, it will be a marker for cancer cells derived from stratified epithelium.
- the presence or absence of the expression or activity of the dermokine- ⁇ / ⁇ protein of the present invention as an index it is possible to determine whether or not a desired cancer cell is a cancer cell derived from a stratified epithelial force. It is.
- the present invention provides a method for examining whether or not a test cell is a cancer cell that also has a stratified epithelial force, using the presence or absence of dermokine-aZjS protein expression or activity as an index.
- the method comprises the following steps (a) and (b).
- test cell is a cancer cell derived from stratified epithelium when the expression level or the activity is changed as compared to a control
- the "measurement” in the above step (a) can be appropriately performed by the above-described method.
- the “control” in the above step (b) usually refers to a normal cell. Specifically, it is a cell that has been previously determined not to be a cancer cell, and is generally a cell derived from a healthy subject. In addition, a cancer cell that has been found in advance not to be a cancer cell derived from a stratified epithelial force can also be used as the “control”.
- cells that have changed as compared with dermokine- ⁇ / ⁇ expression or activity control are cancer cells derived from stratified epithelium, for example, squamous epithelium It can be determined that the cell is a cancer cell.
- the above “change” usually means “increase” and “decrease”, and preferably refers to "decrease”. Therefore, in a preferred embodiment of the present invention, the cell in which the expression or activity of dermokine- ⁇ Z ⁇ is decreased as compared to a control is a cancer cell derived from stratified epithelium, for example, a squamous cell cancer cell. Can be determined.
- the protein of the present invention is considered to be involved in abnormal proliferation and differentiation diseases derived from stratified epithelium.
- stratified epithelium squamous cell carcinoma and basal cell carcinoma derived from stratified squamous epithelium (pseudostratified epithelium in the case of lung cancer) are often found in skin cancer, esophageal cancer, cervical cancer, lung cancer, thymic cancer and the like.
- the protein (gene) of the present invention is predicted to be involved in the degree of cancer progression or division in these cancers, that is, it is useful as a marker for these cancers.
- the “cancer cell from which stratified epithelial force is also derived” preferably refers to the above-mentioned cancer cell.
- the above method of the present invention is effective for squamous cell carcinoma of the lung bronchi (pseudostratified epithelium) which is not originally stratified squamous epithelium.
- the present invention relates to a method for diagnosing squamous cell carcinoma or basal cell carcinoma in a subject, comprising the following steps (a) and (b).
- the above test (diagnosis) method can be performed using a body fluid such as blood as a test sample.
- a body fluid such as blood as a test sample.
- the protein of the present invention is a secretory protein, particularly when the protein of the present invention is secreted in blood, diagnosis of cancer derived from stratified epithelium, for example, esophageal cancer or lung cancer, may be appropriately performed. It is possible to implement.
- the protein of the present invention is considered to be involved in various skin diseases. For example, in a pathological condition such as psoriasis in which epidermal turnover is enhanced, the basal layer is remarkably increased, proliferation is increased, and parakeratosis occurs. In lichen planus, etc. In, hyperkeratosis without granulation and hypertrophy of the granular layer are observed. It is also conceivable that the protein of the present invention (for example, dermokine-aZj8) is involved in diseases caused by abnormal differentiation and proliferation as described above.
- the present invention provides a method for diagnosing a skin disease in a subject, comprising the following steps (a) and (b).
- step (b) when the expression amount or activity in step (b) is increased, it is determined that the skin disease is associated with an increase in the expression or activity of dermokine- ⁇ / ⁇ . You. On the other hand, when the expression level or the activity is decreased, it is determined that the dermokine-aZjS is suffering from a skin disease associated with the decreased expression or activity.
- the “skin disease” usually refers to a disease associated with (caused by) a change in the expression or activity of dermokine- ⁇ / ⁇ protein. More specifically, examples of skin diseases include psoriasis, lichen planus, keratosis, eczema, pruritus, melasma, and inflammatory dermatitis.
- Examples of a biological sample that can be subjected to the above-mentioned diagnostic method include a skin tissue (cells) of a subject, and a sample containing cells or a cell extract derived from the subject. If there is, there is no particular limitation.
- the subject usually refers to a human, but is not particularly limited as long as it is an organism having the protein of the present invention (for example, dermokine- ⁇ / ⁇ ).
- the test and diagnosis method of the present invention for example, a skin disease diagnosis method
- animals such as dogs and cats.
- the expression or activity of dermokine- ⁇ / ⁇ protein is measured by measuring the expression or activity of SSC of a complex containing dermokine- ⁇ / ⁇ protein as a component. Can also be implemented.
- the present invention relates to a dermokine-a protein or a dermokine- ⁇ protein, or a keratinocyte sliver-inducing agent obtained by the above-described screening method. And a method for treating or preventing a disease caused by reduced keratinocyte component-inducing ability.
- the present invention relates to a compound selected from the group consisting of the following (a) to (d), or a (therapeutically effective amount) of a keratinocyte diversion inhibitor obtained by the above-mentioned screening method.
- a method for treating or preventing a disease caused by enhanced keratinocyte dysfunction characterized by administering to a subject.
- the present invention also relates to the use of a dermokine-a protein or a dermokine- ⁇ protein, or a keratinocyte induction agent obtained by the above screening method, in the manufacture of a therapeutic agent for a disease caused by reduced keratinocyte induction induction. About.
- the present invention also relates to a compound selected from the group consisting of the following (a) to (d), or a keratinocyte disulfide inhibitor obtained by the above-mentioned screening method, due to keratinocyte disulfide enhancement.
- a compound selected from the group consisting of the following (a) to (d), or a keratinocyte disulfide inhibitor obtained by the above-mentioned screening method due to keratinocyte disulfide enhancement.
- examples of the disease caused by reduced keratinocyte induction induction include psoriasis vulgaris or actinic keratosis.
- examples of the disease caused by the enhancement of cynocytosis include ichthyosis vulgaris with hyperkeratosis, hereditary ichthyosis vulgaris, wart vulgaris, lichen amyloid, and lichen planus with thickening of the granular layer.
- bullous congenital ichthyosis-like erythroderma can be mentioned bullous congenital ichthyosis-like erythroderma.
- the individual in the treatment or prevention method of the present invention generally refers to a patient with the above-mentioned diseases, and is not particularly limited, but is preferably a human.
- administration to a patient can be performed by a method known to those skilled in the art, such as intraarterial injection, intravenous injection, and subcutaneous injection.
- the dose varies depending on the weight and age of the patient, the administration method, and the like, but those skilled in the art can appropriately select an appropriate dose.
- the compound can be encoded by DNA
- the DNA may be incorporated into a vector for gene therapy to perform gene therapy.
- Examples of gene therapy vectors include, for example, retrovirus vectors, adenovirus vectors, virus vectors such as adeno-associated virus vectors, and non-virus vectors such as ribosomes.
- the target DNA can be administered to a patient by an ex vivo method or an in vivo method using the vector.
- NHEK Normal human embryonic keratinocytes
- KURABO Osaka, Japan
- NHEK cells were cultured in serum-free medium Humedia KG2 (KURABO).
- 293ZEBNA-1 cells were purchased from Invitrogen (San Diego, CA) and maintained in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal calf serum.
- Anti-His antibody Penta'His Antibody.BSA free
- QIAGEN Valencia, CA
- mouse skin cDNA library was constructed and equalized according to the previously described method (Komiya T, Tanigawa Y, Hirohashi S: Anal. Biochem. 254: 23-30, 1997). Briefly, mouse skin cDNA was constructed from total RNA from mouse back skin (8-week-old female BalbZc mice) using a Notl restriction site and a primer Oligo _ ((one)). After amplification, two equalization cycles were performed according to the method previously described (Ko: Nucleic Acids Res. 18: 5705-5711, 1990; Takahashi N, Ko MSH: Genomics 23: 202-210, 1994). The Cot values at each stage of the equalization (El and E2) were 10 and 100, respectively.
- Equalization was assessed in duplicate by quantitative real-time PCR analysis as described below.
- the following gene-specific primer pairs were constructed from the cDNA sequences NM016958, NM027011, NM008401 and NM008508: mouse keratin 14 (5, -GGACGCCCACCTTTCATCTTC-3 '(SEQ ID NO: 9): forward, 5'-ATCTGGCGGTTGGTGGAGG-3 '(SEQ ID NO: 10): reverse direction),
- Mouse keratin 5 (5'-CAGTTCTACATTTGTGTTGCACGTC-3, (SEQ ID NO: 11): forward, 5, -TTGGACAGACTCTGGAGGAAGTCAG-3, (SEQ ID NO: 12): reverse), mouse integrin a -M (5, -TTGAAAGGACCCCAGTGCTGAACTGC- 3, (SEQ ID NO: 13): forward, 5 '-ATGGAGCTGCCCACAATGAGTGGTACAG-3' (SEQ ID NO: 14): reverse), and
- the E2 library was digested with Notl and Sail, and the resulting fragment was digested with pBlueScript KS (-) (
- HT-ISH in 96-well plates was performed as previously described (Komiya T, Tanigawa Y, Hirohashi S: Anal. Biochem. 254: 23-30, 1997). Briefly, adult mouse foot-skin was also newly isolated from 8-week-old female BalbZc mice. The isolated skin was fixed with 1% getyl pyrocarbonate (DEPC) in phosphate buffered saline (PBS) for 1 hour at room temperature. The sample was then dehydrated, embedded, sectioned, and hybridized to mounts and 96-well plates.
- DEPC getyl pyrocarbonate
- PBS phosphate buffered saline
- RNA from various adult mouse tissues was prepared according to the method described by Chomczynski and Sacchi (Chemczynski P, Sacchi N: Anal. Biochem. 162: 23-30, 1997.). Total RNA (20 g) was electrophoresed and transferred to a Hybond-N + membrane (Amersham Pharmacia Biotech, Little Chalfont, U.K.).
- First strand cDNA was prepared from human skin total RNA (Stratagene) using Superscript II reverse transcriptase (Invitrogen).
- the DNA fragment encoding the ORF of human dermokine-a and -j8 was prepared using the 5 'SalI-dermokine-a primer (SEQ ID NO: 17Z primer (SEQ ID NO: 18ZGCGGCCGCCCAAAACTTCACCCACTGCAGAGGG) and the 5' SalI-dermokine- ⁇ primer
- 3'NotI-suprabasin primers (SEQ ID NO: 24Z) were amplified. These primers were designed based on the following GenBank accession numbers: AK003695 (dermokine-a), BC035311 (dermokine-j8), BX112106 (Kdap) And BC063640 (suprabasin).
- normal human epidermal keratinocytes were placed in a dish (2.5 X 10 3 Zcm 2 ) in awake edia KG2 medium (Ca 2+ concentration 0.15 mM, containing pituitary pituitary extract (BPE)). The cells were seeded at a density and cultured for 2 days. The cells were then washed several times with normal Ca 2+ medium (Ca 2+ 0.15 mM) or high Ca 2+ medium (Ca 2+ 1.5 mM) without BPE, respectively. Keratinocytes were then cultured in normal Ca 2+ medium for 2, 4 and 6 days or in high Ca 2+ medium for 2 days. These cells were also prepared using RNeasy Mini Kit (QIAGEN) for total RNA for qRT-PCR. Also, if you want to perform transmission, use TransIT LT1
- keratinocyte (Mirus) the cells were transfused into keratinocytes cultured on 0.15 mM Ca 2+ on the second day.
- Quantitative real-time PCR was performed in duplicate with the QuantiTect SYBR Green PCR Kit (QIAGEN) and the ABI PRISM 7700 sequence Detection system (Applied Biosystems, Foster city, A) by observing the increase in SYBRGreen I dye fluorescence. .
- the primer was designed to match a single real-time PCR thermal profile (95 ° C for 15 minutes and 40 cycles of 95 ° C for 15 seconds and 60 ° C for 1 minute) so that multiple transcripts could be analyzed simultaneously. All data were standardized for an internal standard (daricelaldehyde-3-phosphate dehydrogenase mRNA; A Ct method, User Bulletin 2, Applied Biosystems).
- the set of primers is as follows.
- mice The foot-epidermis of mice is thicker than the epidermis between follicles such as the skin on the back, and its morphology is similar to that of human epidermis. Therefore, the present inventors set out the sections of mouse foot-epidermis (8-week-old Balb / c mice) to identify layer-specific expression of genes in high-throughput in situ hybridization (HT-ISH). It was used. After the sections were placed on each well of a 96-well plastic plate (100 plates; total 9600 sections), a DIG-labeled cRNA probe, which was also prepared for an equalized cDNA library, was hybridized. Hybridization signals were observed in approximately 11,000 out of 9600 sections.
- HT-ISH high-throughput in situ hybridization
- Cyclophilin A, Kdap, prothymosin a, diazepam binding inhibitor, tubulin 13-2 chain homolog, lamin A, nuclear distribution C homolog, desmoplakin, keratin-related protein 16-5, nucleoside diphosphate kinase, small proline rich-like 2 And HT-ISH signals for oral likulin are shown in FIG. 1B as an example.
- the expression of cyclofilin, Kdap, and oral ricklin were localized to the basal layer Z, the basal layer, and the condylar layer, respectively (AL-Daraji WI, Grant KR, Ryan K, Sacton A , Reynolds NJ:
- the present inventors identified a novel cDNA fragment (SK063F08) in which the in situ hybridization signal was specifically detected in the spinous layer of these 116 cDNA clones (FIG. 2A).
- a search was made of a publicly available mouse EST database to identify an EST clone (AK003695) having the entire sequence of SK063F08 (FIG. 2B).
- AK003695 EST clone
- This AK003695 EST contains a 22 bp short 5'-untranslated region (UTR), which encodes 104 amino acids (SEQ ID NO: 53)! /, A 315 bp open reading frame (ORF), and polyadenyl. It is composed of a 324 bp 3'-UTR containing an activation signal!
- the corrected AK081753 EST sequence had a 170 bp short 5'-UTR, a 1554 bp ORF encoding a 517 amino acid protein, and a 320 bp 3'-UTR containing a polyadullation signal! / (FIG. 2B). .
- BMP bone morphogenetic protein
- the gene for Ensembl Human Genome Browseri on chromosome 19ql3.1 [this gene maps to human dermokine- ⁇ and -j8 (ENSG00000161249), which extends over the range of 14-kb.
- human dermokine- ⁇ and -j8 consist of 6 and 16 exons, respectively.
- exon 1 of the dermokine- ⁇ gene has both a putative translation initiation site and a signal sequence and is located between exons 11 and 12 of the dermokine-18 gene, which are transcribed by separate promoters. It is suggested that The putative stop codon was contained within exon 5 of dermokine-a, ie, exon 15 of dermokine-.
- mice dermokine-a / -j8 gene was mapped to ENSMUSG00000036665 on the chromosome 7 in the Ensembl Mouse Genome Browser as ENSMUSG00000036665, a region shared with human 19ql3.1 in synth.
- the exact genomic organization of the mouse dermokine-j8 gene has not been determined due to incomplete information from the available genomic databases, but the same genomic organization has been identified around the mouse dermokine- ⁇ locus.
- keratinocyte-related peptide suprabasin and keratinocyte differentiation-related protein has been mapped to two genes (Fig.3B).
- T basaki M, Obara M, Yoshizato K: Kdap, a novel gene associated with the stratification of the epithelium.
- the suprabasin ⁇ dermokine- ⁇ / -j8 and Kdap genes are in this order in the same direction as transcription.
- the testis-specific dalyseraldehyde-3-phosphate dehydrogenase and ubiquitous GPR43 genes encoding keratinocyte-specific proteins are located upstream of suprabasin and downstream of Kdap, respectively.
- the SignalP server estimated that not only dermokine-a / -j8 but also Kdap and suprabasin had putative signal sequences at their N-termini (FIG. 4A). This has been previously noted in Kdap (Oomizu S, Sahuc F, Asahina K, Inamatsu M, Matsuzaki T, Sasaki M, Obara M, Yoshizato K: Kdap, a novel gene associated with the stratification of the epithelium. Gene. 256: 19-27, 2000.), while the N-terminal hydrophobic sequence of suprabasin is considered as a potential transmembrane domain! /, (Park uT, Lim SE, Jang b, Morasso MI: Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor.J. Biol. Chem.
- the dermokine- ⁇ / —j8, Kdap, and suprabasin genes form a gene complex, and all of their products are secreted from keratinocytes. I want to guess. To test this idea, human dermokine-oV-jS, Kdap and suprabasin (0.7-kb transcript) cDNAs were transformed into mammalian expression vectors.
- the protein was expressed. These fusion proteins were transiently expressed in cultured 293 / EBNA-1 cells and were detected in the culture medium by immunoblotting using an anti-His antibody (FIG. 4B). Interestingly, in the SDS-PAGE gel, the cells detected in the medium were significantly shifted upward in comparison to the estimated molecular mass of the fusion protein, indicating that the secreted protein This suggests that post-translational modification was possibly due to glycosylation and Z or intermolecular disulfide bonds.
- suprabasin- SEAP yields 0.15 mg / L, 0.3 mg / L, 13.5 mg / L, and 15 mg / L, respectively
- the expression pattern of the 0.7-kb and 2.2-kb splicing variants of the suprabasin gene was very similar to that of dermokine-a / -j8 (Suprabasin FIG. 5A). Furthermore, the present inventors examined the expression of these proteins by quantitative RT-PCR (qRT-PCR) (Table 1).
- Table 1 shows the results of quantitative real-time RT-PCR analysis of the expression of dermokine-a, - ⁇ , Kdap and suprabasin in various epithelial tissues.
- Total RNA was prepared from various epithelial tissues from 8-week-old female Balb / c mice and subjected to SYBR Green-based quantitative real-time RT-PCR using primers specific for mouse dermokine- ⁇ -j8 Kdap and suprabasin. Done. All data were normalized for an internal GAPDH mRNA control.
- the present inventors compared the expression of the SSC product in the stratified epithelium in detail, and performed in situ hybridization analysis on serial sections of the epidermis of the mouse foot. Serial sections of eight epidermis were hybridized with antisense or sense cRNA probes for dermokine- ⁇ / j8, Kdap and suprabasin. As shown in Fig. 5B, dermokine- ⁇ / - ⁇ (SK063F08, Fig. 2B), dermokine- j8 probe (j8 probe, Fig. 2B) and suprabasin antisense probe are distributed evenly through the epidermal spinous layer. A hybridization signal occurred.
- the PCDNA3.1-SEAP (His) vector used in Fig. 4 to generate a polyclonal antibody to human dermokine- ⁇ , -j8, Kdap, and Suprabasin used human dermokine- ⁇ , Kdap, Suprabasin was introduced, and Dermokine- ⁇ was deleted from the common part with dermokine- (dermokine-j8- ⁇ C) (Fig. 8A). And expressed transiently.
- the resulting culture medium was purified as a single band using TALON Superflow Metal Affinity Resin (FIG. 8B). Eggs were immunized with these fusion proteins to obtain antisera.
- the mouse dermokine- ⁇ A C-SEAP (His) 6 was immunized to a rat (Wister rat female) to produce monoclonal antibodies (referred to as Anti-hDK mAb and Anti-mDK mAb, respectively).
- the cells were transfected into 293 / EBNA-1 cells, and the obtained culture supernatant was subjected to SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was reacted with Anti-hDK mAb and Anti-mDK mAb, and immunoblot was performed.
- each well was washed once with a phosphate buffer solution containing 0.02% Tween20 (0.02% T-PBS), and the prepared Anti-hDK mAb and Anti-mDK mAb (the supernatant of a non-hybridoma serum-free culture) were added to 50 ⁇ l. 1 was added and incubated at room temperature for 1 hour. The solution in each well was discarded and washed three times with 0.02% T-PBS to immobilize the antibody. Next, each well was treated at 65 ° C for 10 minutes and diluted with PBS. 6.25-50 nM human / mouse dermokine- ⁇ -SEAP (His) or human / mouse dermokine- ⁇ AC-SEAP (His) 50 ⁇ 1
- the alkaline phosphatase activity of C-SEAP (His) was detected.
- the reaction solution is 1420 ARVO
- the measurement was performed at 460 nm with a multilabel counter, Wallacl420 Manager.
- Figure 10A mouse
- Figure 10B human
- Anti-hDK mAb and Anti-mDK mAb bound to dermokine-j8 in a concentration-dependent manner.
- the recombinant protein containing only SEAP hardly bound to the immobilized antibody.
- the column operation was performed at 4 ° C. using an AKTAexplorerlOS system (P-903 pump, UV-900 monitor, pH / C-900 monitor, Frac-901 fraction collector-1; manufactured by Amersham Biosciences).
- the protein in each fraction was subjected to SDS polyacrylamide gel electrophoresis (15% acrylamide gel).
- the present invention has shown that SSCs are expressed in multilayered epithelia and are induced in a differentiation-specific manner. Therefore, it is possible that SSCs are involved in the division and Z or proliferation of epithelial keratinocytes. By creating dermokine knockout mice, the exact physiological role of SSC can be examined. In addition, this gene can be used as a novel marker in the characterization of skin and other multilayered epithelial diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05719773A EP1739171A4 (en) | 2004-03-02 | 2005-03-02 | NEW GENE PARTICIPATING IN EPIDERMISIFICATION AND USE THEREOF |
JP2006510529A JPWO2005083075A1 (ja) | 2004-03-02 | 2005-03-02 | 表皮分化に関与する新規遺伝子、およびその利用 |
US10/591,099 US20070259383A1 (en) | 2004-03-02 | 2005-03-02 | Novel Genes involved in Epidermal differentiation, and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-057559 | 2004-03-02 | ||
JP2004057559 | 2004-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005083075A1 true WO2005083075A1 (ja) | 2005-09-09 |
Family
ID=34909039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003458 WO2005083075A1 (ja) | 2004-03-02 | 2005-03-02 | 表皮分化に関与する新規遺伝子、およびその利用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070259383A1 (ja) |
EP (1) | EP1739171A4 (ja) |
JP (1) | JPWO2005083075A1 (ja) |
WO (1) | WO2005083075A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009121874A (ja) * | 2007-11-13 | 2009-06-04 | Eisai R & D Management Co Ltd | 消化器癌の診断方法 |
WO2016072105A1 (ja) * | 2014-11-04 | 2016-05-12 | 学校法人 杏林学園 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021658A1 (en) * | 1999-09-24 | 2001-03-29 | Human Genome Sciences, Inc. | 32 human secreted proteins |
WO2002008288A2 (en) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002068628A1 (en) * | 2001-02-23 | 2002-09-06 | Human Genome Sciences, Inc. | 70 human secreted proteins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004237766B2 (en) * | 2003-04-30 | 2010-08-19 | Centocor, Inc. | CNGH0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses. |
-
2005
- 2005-03-02 US US10/591,099 patent/US20070259383A1/en not_active Abandoned
- 2005-03-02 EP EP05719773A patent/EP1739171A4/en not_active Withdrawn
- 2005-03-02 JP JP2006510529A patent/JPWO2005083075A1/ja active Pending
- 2005-03-02 WO PCT/JP2005/003458 patent/WO2005083075A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021658A1 (en) * | 1999-09-24 | 2001-03-29 | Human Genome Sciences, Inc. | 32 human secreted proteins |
WO2002008288A2 (en) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002068628A1 (en) * | 2001-02-23 | 2002-09-06 | Human Genome Sciences, Inc. | 70 human secreted proteins |
Non-Patent Citations (6)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009121874A (ja) * | 2007-11-13 | 2009-06-04 | Eisai R & D Management Co Ltd | 消化器癌の診断方法 |
WO2016072105A1 (ja) * | 2014-11-04 | 2016-05-12 | 学校法人 杏林学園 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
US11041146B2 (en) | 2014-11-04 | 2021-06-22 | Masakazu Kurita | Cell having ability to form stratified epithelial tissue, and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
EP1739171A4 (en) | 2008-11-05 |
US20070259383A1 (en) | 2007-11-08 |
EP1739171A1 (en) | 2007-01-03 |
JPWO2005083075A1 (ja) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3981416B2 (ja) | Pca3タンパク質、pca3遺伝子、及びこれらの用途 | |
US20030005471A1 (en) | PAR, a novel marker gene for breast and prostate cancers | |
JPH09507021A (ja) | サブトラクションcDNAライブラリーの作製方法および該作製されたライブラリーの使用 | |
KR101057116B1 (ko) | 포유류에서의 분화 조절제 및 분화 조절 방법 | |
JPH08509118A (ja) | Maxとの相互作用蛋白質並びに関連分子および方法 | |
US7094569B2 (en) | Hair follicle growth factor proteins | |
Hong et al. | Up-regulation of adipogenin, an adipocyte plasma transmembrane protein, during adipogenesis | |
JP4295516B2 (ja) | ガストロカインおよびインヒビターを含むその誘導ペプチド | |
JP2001523455A (ja) | Cdk2タンパク質およびcdk2タンパク質複合体 | |
WO2005083075A1 (ja) | 表皮分化に関与する新規遺伝子、およびその利用 | |
KR960015442B1 (ko) | 맥관인자 | |
Lee et al. | Molecular cloning and expression of human keratinocyte proline-rich protein (hKPRP), an epidermal marker isolated from calcium-induced differentiating keratinocytes | |
US6586581B1 (en) | Prolactin regulatory element binding protein and uses thereof | |
JP2003523723A (ja) | ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法 | |
US5559021A (en) | DNA encoding a novel mammalian transporter homologous to neurotransmitter transporters and uses thereof | |
JPH1087507A (ja) | γ−グルタミルトランスペプチターゼの新規な用途 | |
JP2004525628A (ja) | 新規な天然の抗菌性ペプチド、該ペプチドをコードするヌクレオチド配列及びそれらの使用 | |
JP5378202B2 (ja) | 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー | |
DE60224778T2 (de) | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen | |
WO2009081854A1 (ja) | アレルギー性疾患のバイオマーカーおよびその利用 | |
DE60024862T2 (de) | "insulinabhängiges sequenz dna bindendes protein-1" (irsdbp-1), dafür kodierendes gen und ihre verwendungen | |
JP2006525031A (ja) | Acheron発現の制御方法 | |
EP1180243B1 (en) | Uses of notch related genes | |
JP4531482B2 (ja) | βアミロイド誘導Mib遺伝子 | |
US20070015155A1 (en) | Novel protein usable in screening drug improving type 2 diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510529 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005719773 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005719773 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10591099 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10591099 Country of ref document: US |